

PERSONAL INFORMATION **Jan Cornelissen**

WORK EXPERIENCE

- 1987- 1990 **Fellow Internal Medicine**
Hospital "De Lichtenberg", Amersfoort (Netherlands)
- 1987- 1990 **Fellow Internal Medicine**
University Hospital Utrecht (Netherlands)
- 1999- 1999 **Sabbatical leave**
Fred Hutchinson's Cancer Research Center, Seattle, WA, USA (United States)
- 2011- Present **Hematology Educational and Department Deputy Head**
Department of Hematology, ErasmusMC (Netherlands)
- 2005- Present **Professor of Hematology**
Chair in Hematopoietic Stem Cell Transplantation (Netherlands)
- 1994- Present **Hematologist, Member of the Staff of the Department of Hematology**
Erasmus MC/Daniel den Hoed Cancer Center, head of hematopoietic stem cell transplantation program (Netherlands)
- 1991- 1993 **Hematologist, Member of the Staff of the Department of Hematology**
University Hospital Utrecht (Netherlands)
- 1987- 1991 **Research fellow, Department of Infectious Diseases**
State University Utrecht (Netherlands)
- 1990- 1991 **Assistant Professor of Medicine**
Department of Oncology, University of Utrecht (Netherlands)
- 2014- Present **Chair HOVON**
HOVON (Hematology-oncology for adults in the Netherlands/Belgium) (Netherlands)

EDUCATION AND TRAINING

- 1977- **Athenaeum Beta**
()

- 1985- Medical Licence (State University Utrecht)
()
- 1986- E.C.F.M.G. examination (U.S. Embassy - The Hague)
()
- 1985- 1990 University Hospital Utrecht, Department of Medicine, fellowship Internal
Medicine
()
- 1990- Board certification Internal Medicine
()
- 1993- Board certification Hematology
()
- 1991- PhD
()
Antibody mediated cross-protection against endotoxin. (State University Utrecht)
Promoter: Prof. J. Verhoef

ADDITIONAL INFORMATION

- Expertise** Hematopoietic stem cell transplantation (alternative donors; immune reconstitution; thymopoiesis; opportunistic infections)
Treatment of leukemia and malignant lymphoma
Acute Myeloid and Lymphoblastic Leukemia (new treatment modalities; hematopoietic stem cell transplantation)
- Publications** Cornelissen JJ, Golterman AFL, Kerckhaert JAM, Van de Wiel A, Imhof JW.
Fixed IgM reduction in plasma exchange: a standardized method for calculating the volume to be removed per session.
Plasma Ther Transf Techn 1984;5:365-70.
Cornelissen JJ, Haanstra W, Haarman HJTM, Derksen RHWM.
Plasma exchange in rhabdomyolysis.
Intens Care Med 1989;15:528-29.
Cornelissen JJ, Oosterlaken TAM, Schellekens J, Torensma R, Rozenberg-Arska M, Kraaijeveld CA, Verhoef J.
Discrimination by rabbit anti-idiotypic antibodies of two murine IgM monoclonal antibodies directed against lipid A.
J Immunol Methods 1990;130:141-47.
Ronday M, De Vries JW, Damen J, Cornelissen JJ, Nieuwenhuis HK.
Coronary artery surgery in a patient with hemophilia A.
Neth J Cardiol 1990;3:23-24.
Cornelissen JJ, Van Kessel C, Brouwer E, Kraaijeveld CA, Verhoef J.
Inhibition by lipid A specific monoclonal antibodies of priming of human polymorphonuclear

leucocytes by endotoxin.
J Med Microbiol 1991;34:233-38.

Cornelissen JJ, Bakker LJ, Van der Veen MJ, Rozenberg-Arska M, Bijlsma JW.
Nocardia asteroides pneumonia complicating low dose methotrexate for refractory rheumatoid arthritis.
Ann Rheum Dis 1991;50:642-44.

Cornelissen JJ, De Graeff A, Neijt JP, Tjia P, Vendrik CPJ, Witteveen PO, Zonnenberg BA.
Behandelingsrichtlijnen voor oncologische patiënten, Academisch Ziekenhuis Utrecht, Utrecht, 1991.

Cornelissen JJ, Schellekens JFP, Kraaijeveld CA, Verhoef J.
Life-saving immunotherapy with cross-reactive monoclonal antibodies against endotoxin: a critical evaluation of experimental and clinical studies.
Neth J Med 1991;39:170-6.

Cornelissen JJ.
Immuuntherapie met kruisreagerende monoclonale antilichamen gericht tegen endotoxine van gram-negatieve bacteriën. In: De Lange B., Rommes J.H., Zwaveling J.H. (red.).
Intensive Care Captia Selecta 1991.
Utrecht Wetensch Uitg Venticare 1991:223-27.

Cornelissen JJ, Hustinx WNM, Van Asbeck BS, Hoepelman IM, Speelman P, Van Asten P, Visser M, Schellekens JFP, Verhoef J.
Indicaties voor immuuntherapie met monoclonale anti-endotoxine antistoffen bij patiënten met sepsis veroorzaakt door gramnegatieve bacteriën.
Pharmaceutisch Weekblad 1991;36:126.

Cornelissen JJ.
Antibody mediated cross-protection against endotoxin.
State University Utrecht 1991.

- CURRICULUM VITAE -
17

Cornelissen JJ, De Graeff A, Verdonck LF, Branger T, Rozenberg-Arska M, Dekker AW, Verhoef J.
Imipenem-cilastatin versus gentamicin combined with either cefuroxime or cephalotin as initial therapy for febrile neutropenic patients.
Antimicrob Agents Chemother 1992;36:801-7.

Verdonck LF, Cornelissen JJ, Smit J, Lepoutre J, De Gast GC, Dekker AW, Rozenberg-Arska M.
Successful foscarnet therapy for acyclovir-resistant mucocutaneous infection with herpes simplex virus in a recipient of allogeneic bone marrow transplantation.
Bone Marrow Transplantation 1993;11:177-79.

Cornelissen JJ, Mäkel I, Algra A, Benaïssa-Trouw BJ, Schellekens JFP, Kraaijeveld CA, Verhoef J.
Protection against lethal endotoxemia by anti-lipid A murine monoclonal antibodies: comparison of efficacy with that of human anti-lipid A monoclonal antibody HA-1A.
The Journal of Infectious Diseases 1993;167:876-81.

Cornelissen JJ, Maassen K, Van Emst L, Weers PMM, Harmsen M, Benaïssa-Trouw BJ, Oosterlaken TAM, Kraaijeveld CA, Verhoef J.
Anti-idiotypic immunization provides protection against lethal endotoxaemia in BALB/c mice.
Immunology 1993;79:673-80.

Verdonck LF, Cornelissen JJ, Dekker AW, Rozenberg-Arska M.
Acute abdominal pain as a presenting symptom of varicella-zoster virus infection in recipients of bone marrow transplants.
Clinical Infectious Diseases 1993;16:190-91.

Cornelissen JJ, Mäkel I, Algra A, Benaïssa-Trouw BJ, Schellekens JFP, Kraaijeveld CA, Verhoef J.
Protection against lethal endotoxemia by anti-lipid A murine monoclonal antibodies. Reply.
Journal of Infectious Diseases 1993;168:1594.

Cornelissen JJ, Sonneveld P, Schoester M, Raaijmakers HGP, Nieuwenhuis HK, Dekker AW, Lokhorst HM.
MDR-1 expression and response to Vincristine, Doxorubicin and Dexamethasone chemotherapy in

multiple myeloma refractory to alkylating agents
 Journal of Clinical Oncology 1994;12:115-19.

Bouter AS, Kok KPM, Cornelissen JJ, Schellekens JFP, Van der Hoek YY, Snippe H, Verhoef J.
 Antibiotics enhance binding of lipid A-specific murine monoclonal antibody E5 to Gram-negative bacteria.
 International Journal of Antimicrobial Agents 1994;4:191-95.

Vlasveld LT, Cornelissen JJ, Dellelijn PLI, Joesse MV, Van den Bent MJ.
 Corticale blindheid tijdens behandeling met Ciclosporine.
 Ned T Geneesk 1994;138;2057-61.

Cornelissen JJ, Rozenberg-Arska M, Dekker AW.
 Discontinuation of Intravenous Antibiotic Therapy During Persistent Neutropenia in Patients Receiving Prophylaxis with Oral Ciprofloxacin.
 Clinical Infectious Diseases 1995;21;1300-02.

- CURRICULUM VITAE -
 18

Cornelissen JJ.
 Chronische myeloïde leukemie: recente ontwikkelingen op het gebied van pathogenese, diagnostiek en behandeling met behulp van Interferon of intensieve chemotherapie. Syllabus PAO: Nascholingscursus. Ontwikkelingen in de klinische Hemato-Oncologie. HOVON 1995:67-69.

Harms RE, Cornelissen JJ, Visch LL.
 Orthodontische extractie bij een patiënte met een diepe thrombocytopenie.
 Nederlands Tijdschrift voor Tandheelkunde 1996;103;92-93.

Breems DA, Van Hennik PB, Kusadasi N, Boudewijn A, Cornelissen JJ, Sonneveld P, Ploemacher RE.
 Individual Stem Cell Quality in Leukapheresis Products is Related to the Number of Mobilized Stem Cells.
 Blood 1996;87:12;5370-78.

Löwenberg B, Cornelissen JJ, Sonneveld P.
 Acute en chronische Leukemie.
 Oncologie 1996;5e herziene druk;595-612.

Cornelissen JJ.
 Chronische myeloïde leukemie: recente ontwikkelingen op gebied van pathogenese, diagnostiek en behandeling met behulp van Interferon of intensieve chemotherapie.
 Nederlands Tijdschrift voor Klinische Chemie 1996;21;216-18.

Liem GS, Cornelissen JJ, Oudshoorn M, Sintnicolaas K, Löwenberg B, Hagenbeek A.
 Allogene transplantaties met beenmerg van onverwante donors; minder complicaties, meer donors.
 Ned Tijdschr Geneesk 1997;141;1553-56.

Cornelissen JJ, Löwenberg B.
 Ontwikkelingen in de behandeling van patiënten met chronische myeloïde leukemie.
 Ned Tijdschr Geneesk 1997;141;1904-09.

Cornelissen JJ, Wognum AW, Ploemacher RE, Frassoni F, Wagemaker G, Hagemeyer G, Löwenberg B.
 Efficient long-term maintenance of chronic myeloid leukemic cobblestone area forming cells on a murine stromal cell line.
 Leukemia 1997;11;126-33.

Lokhorst HM, Schattenberg A, Cornelissen JJ, Thomas LLM, Verdonck LF.
 Donor leucocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation
 Blood 1997;90;4206-11.

Oudshoorn M, Cornelissen JJ, Fibbe WE, De Graeff-Meeder ER, Lie JLWT, Schreuder GMTh, Sintnicolaas K, Willemze R, Vossen JMJJ, Van Rood JJ.
 Problems and possible solutions in finding an unrelated bone marrow donor. Results of consecutive searches for 240 Dutch patients.

Bone Marrow Transplantation 1997;20:1011-17.

Sonneveld P, Laméris JS, Cornelissen JJ, Ogilvie A, Löwenberg B.

Color-flow imaging sonography of portal and hepatic vein flow to monitor fibrinolytic therapy with r-TPA for veno-occlusive disease following myeloablative treatment.

Bone Marrow Transplantation 1998;21:731-34.

- CURRICULUM VITAE -

19

Cornelissen JJ, Fibbe WE, Schattenberg AVMB, Petersen EJ, Willemze R, De Witte ThJM, Löwenberg B, Verdonck LF, V.d. Biezen A, Brand R.

A retrospective Dutch study comparing T-cell depleted allogeneic blood stem cell transplantation vs T-cell depleted allogeneic bone marrow transplantation.

Bone Marrow Transplantation 1998;21:S66-S70.

Leenders ACAP, Daenen S, Jansen RLH, Hop WCJ, Löwenberg B, Wijermans PW, Cornelissen JJ, Herbrecht R, Van der Lelie J, Hoogsteden HC, Verbrugh HA, De Mari S.

Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections.

British Journal of Haematology 1998;103:205-12.

Cornelissen JJ, Ploemacher RE, Wognum AW, Borsboom A, Kluin-Nelemans JC, Hagemeyer A, Löwenberg B.

An in-vitro model for cytogenetic conversion in CML: Interferon-Alpha preferentially inhibits the outgrowth of malignant stem cells preserved in long-term culture.

J. Clin. Invest. 1998;102:976-83.

Van Gool AR, Bannink M, Cornelissen JJ, Kruit WHJ.

Gebruik van interferon kan psychische bijwerkingen veroorzaken.

Kwartaalblad voor Waldenström- en Kahlerpatiënten 1998;16:13-15.

Van den Bent MJ, Bos GMJ, Sillevius Smitt PAE, Cornelissen JJ.

Eythropoietin induced visual hallucinations after bone marrow transplantation.

Journal of Neurology 1999;246:614-16.

Gadisseur APA, Lamers CHJ, Gratama JW, Bolhuis RLH, Cornelissen JJ.

Expression of the T-cell activation antigen CD134 (OX40) does not predict acute graft-versus-host disease in T-cell depleted bone marrow transplantation.

Bone Marrow Transplantation 1999;23:1013-17.

Cornelissen JJ.

Chronische myeloïde leukemie: eerst interferon of direct transplanteren ?

Syllabus HOVON-nascholingscursus 1999:35-38.

Lokhorst HM, Sonneveld P, Cornelissen JJ, Joosten P, Van Marwijk Kooij M, Meinema J,

Nieuwenhuis HK, Van Oers MHJ, Richel DJ, Segeren CM, Veth G, Verdonck LF, Wijermans PW.

Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.

Bone Marrow Transplantation 1999;23:317-22.

Verstegen MMA, Cornelissen JJ, Terpstra W, Wagemaker G, Wognum AW.

Multilineage outgrowth of both malignant and normal hematopoietic progenitor cells from individual chronic myeloid leukemia patients in immunodeficient mice.

Leukemia 1999;13:618-28.

Segeren CM, Sonneveld P, Van der Holt B, Baars JW, Biesma DH, Cornelissen JJ, Croockewit AJ,

Dekker AW, Fibbe WE, Löwenberg B, Van Marwijk Kooij M, Van Oers MHJ, Richel DJ, Schouten HC, Vellenga E, Verhoef GEG, Wijermans PW, Wittebol S, Lokhorst HM.

Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma.

British Journal of Haematology 1999;105:127-30.

- CURRICULUM VITAE -

20

Bruaset I, Levendag PC, Vriens JPM, Planting ASTh, Cornelissen JJ.
Tumorthherapie. Uitgeverij van der Wees, 1999.

In: Tandheelkunde bij de oncologische patiënt: preventie en behandeling: 53-85
Van Gool AR, Kruit WHJ, Cornelissen JJ, Berk L, Eggermont AMM, Bannink M.
Management of psychiatric events with immunotherapy with interferon-alfa.
Acta Neuropsychiatrica 1999;120-24.

Van den Bent MJ, Bos GMJ, Sillevius Smitt PAE, Cornelissen JJ.
Erythropoietin induced visual hallucinations after bone marrow transplantation.
Journal of Neurology 1999;246;614-16.

Niesters HG, Van Esser J, Fries E, Wolthers KC, Cornelissen JJ, Osterhaus AD.
Development of a Real-Time Quantitative Assay for Detection of Epstein-Barr Virus.
Journal of Clinical Microbiology Feb 2000;38;712-15.

De Brabander J, Cornelissen JJ, Sillevius Smitt PAE, Vecht ChJ, Van den Bent MJ.
Increased incidence of neurological complications in patients receiving an allogeneic bone marrow
transplantation from alternative donors.
Journal of Neurological Neurosurgery and Psychiatry 2000;68;36-40.

Broers AE, Van der Holt R, Van Esser JW, Gratama J-W, Henzen-Logmans S, Kuenen-Boumeester
V, Löwenberg B, Cornelissen JJ.
Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly
effective prevention of CMV disease after allogeneic T-cell-depleted stem cell transplantation.
Blood 2000;95;2240-45.

De Witte Th, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N, Ruutu T, Ljungman P,
Gratwohl A, Runde V, Niederwieser D, Van Biezen A, Devergie A, Cornelissen J, Jouet J-P, Arnold
R, Apperley J.
Hematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary
acute myeloid leukemias. A report on behalf of the Chronic Leukemia Working Party of the
European Group for Blood and Marrow Transplantation.
British Journal of Haematology 2000;110;620-30.

Van Hennik PB, Breems DA, Kusadasi N, Slaper-Cortenbach IC, Van den Berg H, Van der Lelie HJ,
Schipperus MR, Cornelissen JJ and Ploemacher RE.
Stroma-supported progenitor production as prognostic tool for graft failure following autologous stem
cell transplantation.
British Journal of Haematology 2000;111;674-84.

Cornelissen JJ, Löwenberg B.
Developments in T-cell depletion of allogeneic stem cell grafts.
Current Opinions in Hematology 2000;7;348-52.

Cahn JY, Labopin M, Sierra J, Blaise D, Reiffers J, Ferrant A, Bergmann L, Visani G, Cornelissen
JJ, De Witte T, Bosi A, Frassoni F, Gorin NC.
No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloid
leukaemia in first remission. Acute Leukemia Working Party of the Europeaan Group for Blood and
Marrow Transplantation (EBMT).
British Journal of Haematology 2000;110;308-14.

- CURRICULUM VITAE -
21

Lokhorst HM, Schattenberg A, Cornelissen JJ, Van Oers MH, Fibbe W, Russell I, Donk NW,
Verdonck LF.
Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem cell transplantation:
predictive factors for response and long-term outcome.
Journal of Clinical Oncology 2000;18;3031-37.

Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ, Gale RP, Goldman
JM, Loberiza FR, Hertenstein B, Klein JP, Montserrat E, Zhang MJ, Ringden O, Tomany SC,
Rowlings PA, Van Hoef ME, Gratwohl A.
Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic

transplantation. IBMTR Histocompatibility and Stem Cell Society Working Committee and the European Group for Blood and Marrow Transplantation (EBMT).
 Blood 2000;95:3702-09.

Janssen JJ, Van Rijn RS, Van der Holt B, Schuurhuis GJ, Vellenga E, Verhoef GE, Ossenkoppele GJ, Van den Berg E, Hagemeijer A, Slater R, Nieuwint AW, Cornelissen JJ.
 Mobilisation of haemopoietic progenitors in CML: a second course of intensive chemotherapy does not improve Ph-negativity in stem cell harvests.
 Bone Marrow Transplantation 2000;25:1147-55.

Van Hennik PB, Breems DA, Kusadasi N, Slaper-Cortenbach IC, van den Berg H, van der Lelie HJ, Schipperus MR, Cornelissen JJ, Ploemacher RE.
 Stroma-supported progenitor production as a prognostic tool for graft failure following autologous stem cell transplantation.
 Br J Haematol 2000;111:674-84.
 Cornelissen JJ.
 Interferon, Ara-C en tyrosine kinase remmers. Nascholingscursus Ontwikkelingen in de Klinische Hemato-Oncologie.
 Syllabus 2001;48-49.
 Van Iperen CE, Cornelissen JJ.
 Bone marrow aspiration, a dangerous procedure ?
 Neth J Med 2001;59:4-5.

Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Björkstrand B, Blade J, Cornelissen JJ, de Laurenti A, Facon T, Ljungman P, Michallet M, Niederwieser D, Powles R, Feiffers J, Russell NH, Samson D, Schaefer UW, Schattenberg A, Tura S, Verdonck LF, Vernant JP, Willemze R, Volin L.
 Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-1993 and 1994-1998 at European Group for Blood and Marrow Transplantation centres.
 Br J Haematol 2001;113:209-16.

Björkstrand B, Svensson H, Goldschmidt H, Ljungman P, Apperley J, Mandelli F, Marcus R, Boogaerts M, Alegre A, Remes K, Cornelissen JJ, Bladé J, Lenhoff S, Iriando A, Carlson K, Sweetenham J, Volin L, Littlewood T, Goldstone AH, San Miguel J, De Witte Th, Gahrton G.
 Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: A retrospective registry study from the European group for blood and marrow transplantation.
 Bone Marrow Transplant 2001;27:511-15.

- CURRICULUM VITAE -
 22

Van Esser JWJ, Niesters HGM, Thijsen SFT, Meijer E, Osterhaus ADME, Wolthers KC, Boucher ChAB, Gratama JW, Budel LM, Van der Holt B, Van Loon AM, Löwenberg B, Verdonck LF, Cornelissen JJ.
 Molecular quantitation of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr Virus associated lymphoproliferative disease after allogeneic stem cell transplantation.
 Br J Haematol 2001;113:814-21.

Cornelissen JJ, Carston M, Kollman C, King R, Dekker AW, Löwenberg B, Anasetti C.
 Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: storing graft versus leukemia effect and risk factors determining outcome.
 Blood 2001;97:1572-77.

Van Esser JWJ, Van der Holt B, Meijer E, Niesters HGM, Trenschele R, Thijsen SFT, Van Loon AM, Frassoni F, Bacigalupo A, Schaefer UW, Osterhaus ADME, Gratama JW, Löwenberg B, Verdonck LF, Cornelissen JJ.
 Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT.
 Blood 2001;98:972-78.

Burgers JA, Sluiter JF, De Jong DMW, Cornelissen JJ, Van Meerbeeck JP.
Pseudoparasitic pneumonia after bone marrow transplantation.
Neth J Med 2001;59:170-76.

Gratama JW, Van Esser JWJ, Lamers CHJ, Tournay C, Löwenberg B, Bolhuis RLH, Cornelissen JJ.
Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in
T-cell-depleted stem cell grafts and after transplantation: identification of patients at risk for
progressive CMV infection.
Blood 2001;98:1358-64

Van Belkum A, Goessens W, Van der Schee C, Lemmens-den Toom N, Vos MC, Cornelissen JJ,
Lugtenburg E, De Marie S, Verbrugh H, Löwenberg ,Endtz H.
Rapid emergence of Ciprofloxacin-resistant enterobacteriaceae containing multiple Gentamicin
resistance-associated integrons in a Dutch hospital.
Emerging Infectious Diseases 2001;7:862-71.

De Witte T, Pikkemaat F, Hermans J, Van Biezen A, Mackinnan S, Cornelissen J, Gratwohl A,
Delforge M, Iriondo A, Kuentz M, Harousseau J, Fauser A, Wandt H, Runde V, Niederwieser D,
Apperley J, for the EBMT, CLWP-MDS subcommittee, University Medical Center, Nijmegen, The
Netherlands.
Genotypically nonidentical related donors for transplantation of patients with myelodysplastic
syndromes: comparison with unrelated donor transplantation and autologous stem cell
transplantation.
Leukemia 2001;15:1878-84.

Cornelissen JJ, Brand HS.
Kwaadaardige aandoeningen van het immuunsysteem. 2001.
In: Brand H.S., Diemen D.E. van, Makkes P.C. (red.), Algemene ziekteleer voor tandartsen.
Houten/Diegem: Bohn Stafleu van Loghum, pp 59-66.

- CURRICULUM VITAE -
23
Cornelissen JJ.
Incidence and Risks of EBV Viremia after Allogeneic Stem Cell Transplantation. 2001.
In: Educational Book, 27th Annual Meeting European Group for Blood and Marrow Transplantation
and 17th Meeting of the Nurses Group, pp 28-29.
Cornelissen JJ.
Manipulation of Allogeneic Peripheral Blood Stem Cells Technical Possibilities and Medical
Concepts. 2001. In: Educational Book, 27th Annual Meeting European Group for Blood and Marrow
Transplantation and 17th Meeting of the Nurses Group, pp 34-36.

Gratama JW, Cornelissen JJ. Potential clinical utility of monitoring cytomegalovirus-specific T
lymphocytes in allogeneic stem cell transplantation. Clinical and Applied Immunology Reviews
2001;2:17-32.

Somers JAE, Shamelian SOA, Löwenberg B, Ossenkoppele GJ, Cornelissen JJ.
STI571: een nieuwe dimensie in de behandeling van chronische myeloïde leukemie.
Ned Tijdschr Geneeskd 2002;146:128-32.

Guardiola P, Runde V, Bacigalupo A, Ruutu T, Locatelli F, Boogaerts MA, Pagliuca A, Cornelissen
JJ, Schouten HC, Carreras E, Finke J, Van Biezen A, Brand R, Niederwieser D, Gluckman E, De
Witte TM.
Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized
peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling
donor in myelodysplastic syndromes. Blood 2002;99:4370-78.

Van Esser JWJ, Niesters HG, Van der Holt B, Meijer E, Osterhaus AD, Gratama JW, Verdonck LF,
Löwenberg B, Cornelissen JJ.
Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and
preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood
2002;99:4364-69.

Harder H, Cornelissen JJ, Van Gool AR, Duivenvoorden HJ, Eijkenboom WHM, Van den Bent MJ.

Cognitive functioning and quality of life in long-term adult survivors of bone marrow transplantation. *Cancer* 2002;95:183-92.

Cornelissen JJ.

Immune reconstitution after allogeneic transplantation: clinical and experimental findings. *Haematologica* 2002;87:133-37.

Broers AEC, Meijerink JPP, Van Dongen JJM, Posthumus SJ, Löwenberg B, Braakman E, Cornelissen JJ.

Quantification of newly developed T cells in mice by real-time quantitative PCR of T-cell receptor rearrangement excision circles.

Experimental Hematology 2002;30:745-50.

Broers AEC, Gratama JW, Löwenberg B, Cornelissen JJ.

Lymphocyte recovery following allogeneic stem cell transplantation: new possibilities for improvement.

Clinical and Applied Immunology Reviews 2002;2:217-27.

- CURRICULUM VITAE -

24

Van Agthoven M, Groot MT, Verdonck LF, Lowenberg B, Schattenberg AV, Oudshoorn M, Hagenbeek A, Cornelissen JJ, Uyl-de Groot CA, Willemze R.

Cost analysis of HLA-identical sibling and voluntary unrelated allogeneic bone marrow and peripheral blood stem cell transplantation in adults with acute myelocytic leukaemia or acute lymphoblastic leukemia.

Bone Marrow Transplant 2002;30:243-51.

Somers JA, Shamelian SO, Lowenberg B, Ossenkoppele GJ, Cornelissen JJ.

STI571: a new dimension in the treatment of chronic myeloid leukemia.

Ned Tijdschr Geneesk 2002;146:128-32 (Dutch).

Cornelissen JJ

Prevention and treatment of resistance to imatinib (Glivec) in Chronic Myeloid Leukemia.

Nascholingscursus Ontwikkelingen in de Klinische Hemato-Oncologie. Syllabus 2003:25-26.

O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer Th, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot Ph, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ.

Interferon and low-dose Cytarabine compared with Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia.

N Engl J Med 2003;348:994-1004.

Lokhorst HM, Segeren CM, Verdonck LF, Van der Holt B, Raymakers R, Van Oers MH, Barge RM, Schouten HC, Westveer PH, Steijart MM, Cornelissen JJ, Sonneveld P; Dutch-Belgian Hemato-Oncology Cooperative Study.

Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM.

J Clin Oncol 2003;21:1728-33.

Becker MJ, Lugtenburg EJ, Cornelissen JJ, Van der Schee C, Hoogsteden HC, De Marie S.

Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis.

Br J Haematol 2003;121:448-57.

Gratama JW, Cornelissen JJ.

Diagnostic potential of tetramer-based monitoring of cytomegalovirus-specific CD8+ T lymphocytes in allogeneic stem cell transplantation.

Clin Immunol 2003;106: 29-35.

Meij P, Van Esser JW, Niesters HG, Van Baarle D, Miedema F, Blake N, Rickinson AB, Leiner I, Pamer E, Löwenberg B, Cornelissen JJ, Gratama JW.

Impaired recovery of Epstein-Barr virus (EBV)-specific CD8+ T lymphocytes after partially T depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive

EBV reactivation with lymphoproliferative disease.

Blood 2003;101:4290-97.

- CURRICULUM VITAE -

25

Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE, Cornelissen JJ, Schaafsma MR, Van Oers MH, Wijermans PW, Fibbe WE, Wittebol S, Schouten HC, Van Marwijk Kooy M, Biesma DH, Baars JW, Slater R, Steijart MM, Buijt I, Lokhorst HM; Dutch-Belgian Hemato-Oncology Cooperative Study Group.

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective study randomized phase III study.

Blood 2003;101:2144-51.

Van den Hoogen BG, Van Doornum GJ, Fockens JC, Cornelissen JJ, Beyer WE, De Groot R, Osterhaus AD, Fouchier RA.

Prevalence and clinical symptoms of human metapneumovirus infection in hospitalized patients.

J Infect Dis 2003;188:1571-77.

Gratama JW, Cornelissen JJ.

Clinical utility of tetramer-based immune monitoring in allogeneic stem cell transplantation.

BioDrugs 2003;17:325-38.

Meijer E, Cornelissen JJ, Löwenberg B, Verdonck LF.

Antithymocyteglobulin as prophylaxis of graft-failure and graft-versus-host disease in recipients of partially T-cell-depleted grafts from matched unrelated donors: a dose-finding study.

Exp Hematol 2003;31:1026-30.

Cornelissen JJ, Van der Holt B, Petersen EJ, Vindelov L, Russel CA, Hoglund M, Maertens J, Schouten HC, Braakman E, Steijaert MM, Zijlmans MJ, Slaper-Cortenbach I, Boogaerts MA, Löwenberg B, Verdonck LF.

A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies.

Exp Hematol 2003;31:855-64.

Commeren DL, Van Soest PL, Karimi K, Löwenberg B, Cornelissen JJ, Braakman E.

Paradoxical effects of interleukin-10 on the maturation of murine myeloid dendritic cells.

Immunology 2003;110:188-96.

Van Kooij B, Thijsen SF, Meijer E, Niesters HG, Van Esser JW, Cornelissen JJ, Verdonck LF, Van Loon AM.

Sequence analysis of EBV DNA isolated from mouth washings and PBMCs of healthy individuals and blood of EBV-LPD patients.

J Clin Virol 2003;28:85-92.

Broers AE, Posthumus-van Sluijs SJ, Spits H, Van der Holt B, Löwenberg B, Braakman E, Cornelissen JJ.

Interleukin-7 improves T-cell recovery after experimental T-cell-depleted bone marrow transplantation in T-cell-deficient mice by strong expansion of recent thymic emigrants.

Blood 2003;102:1534-40.

Lokhorst HM, Wu K, Verdonck LF, Laterveer LL, van de Donk NW, van Oers MH, Cornelissen JJ, Schatenberg AV.

The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusion in multiple myeloma.

Blood 2004;103:4362-64.

- CURRICULUM VITAE -

26

Cornelissen JJ.

Hematopoietic reconstitution after hematopoietic stem cell transplantation.

In: Clinical Bone Marrow and Blood Stem Cell Transplantation. Third Edition, 2004, Cambridge University Press, pp 160-193. Editors: Atkinson, Champlin, Ritz, Fibbe, Ljungman and Brenner.

Tiercy J-M, Passweg J, Van Biezen A, Zander A, Kröger N, Gratwohl A, Chapuis B, Helg C, Brinch L, Cornelissen JJ, Oudshoorn M, Ruutu T, Volin L, Niederwieser D, Roosnek E, on behalf of the Chronic Leukemia Working Party of the European Blood and Marrow Transplant Group (EBMT). Isolated HLA-C mismatches in unrelated donor transplantation for CML. *Bone Marrow Transplantation* 2004;34:249-55.

Cornelissen JJ.
Molecular monitoring of EB-positive lymphoma. *Blood* 2004;104: 9.

Wils EJ, Cornelissen JJ.
Thymopoiesis following allogeneic stem cell transplantation: new possibilities for improvement. *Blood Reviews* 2005;19:89-98.

Van Walraven SM, Heemskerk MBA, Lie JLWT, Barge RMY, Cornelissen JJ, Egeler RM, Verdonck LF, Wulffraat N, Oudshoorn M.
The importance of identifying a back-up donor for unrelated stem cell transplantation. *Bone Marrow Transplantation* 2005;35:437-40.

Broers AE, Van der Holt B, Haze S, Braakman E, Gratama JW, Löwenberg B, Cornelissen JJ.
A comparison of postengraftment infectious morbidity and mortality after allogeneic partially T-cell depleted peripheral blood progenitor cell transplantation versus T cell-depleted bone marrow transplantation. *Experimental Hematology* 2005;33:912-19.

Visser AM, van Doornum GJJ, Cornelissen JJ, van den Bent MJ.
Severe amnesia due to HHV-6 encephalitis after allogeneic stem cell transplantation. *European Neurology* 2005;54:233-34.

Cornelissen JJ and Löwenberg B.
Role of allogeneic stem cell transplantation in current treatment of acute myeloid leukemia. *Hematology (American Society of Hematology Educational Program)* 2005;151-55.

De Beukelaar JW, van Arkel C, van den Bent MJ, van t Veer MB, van Doornum GJ, Cornelissen JJ, Sillevius Smitt PA, Gratama JW.
Resolution of EBV+ CNS lymphoma with appearance of CSF EBV-specific T cells. *Annals of Neurology* 2005;58:788-92.

Van der Straaten HM, van Biezen A, Brand R, Schattenberg AV, Egeler RM, Barge RM, Cornelissen JJ, Schouten HC, Ossenkoppele GJ, Verdonck LF, Netherlands Stem Cell Transplant Registry TYPHON.
Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities. *Haematologica* 2005;90:1339-45.

- CURRICULUM VITAE -

27

Visser AM, Kappers-Klunne MC, Cornelissen JJ, van den Bent MJ, Taal W.
Een patiënte met sinustrombose door paroxismale nachtelijke hemoglobinurie. *Nederlands Tijdschrift voor Geneeskunde* 2005;149:1528-32.

Harder H, van Gool AR, Cornelissen JJ, Duivenvoorden HJ, Eijkenboom WM, Barge RM, van den Bent MJ.
Assessment of pre-treatment cognitive performance in adult bone marrow or haematopoietic stem cell transplantation patients: a comparative study. *European Journal of Cancer* 2005;41:1007-16.

Heemskerk MBA, van Walraven SM, Cornelissen JJ, Barge RMY, Bredius RGM, Egeler RM, Tj Lie JLW, Révész T, Sintnicolaas K, Wulffraat NM, Donker AE, Hoogerbrugge PM, van Rood JJ, Claas FHJ, Oudshoorn M.
How to improve the search for an unrelated haematopoietic stem cell donor. Faster is better than more! *Bone Marrow Transplantation* 2005;35:645-52.

Gahrton G, Iacobelli S, Apperley J, Bandini G, Björkstrand B, Bladé J, Boiron JM, Cavo M,

Cornelissen J, Corradini P, Kröger N, Ljungman P, Michallet M, Russell NH, Samson D, Schattenberg A, Sirohi B, Verdonck LF, Violin L, Zander A, Niederwieser D.
The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants.
Bone Marrow Transplantation 2005;35:609-17.
Stem Cell Trialists Collaborative Group.
Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials.
Journal of Clinical Oncology 2005;23:5074-87.
Ossenkoppele GJ, Cornelissen JJ.
Glivec® (imatinib) bij de behandeling van chronische myeloïde leukemie (CML).
Van Zuiden Communications BV, Alphen aan den Rijn, 2005.
Visser AM, van Doornum GJ, Cornelissen JJ, van den Bent MJ.
Severe amnesia due to HHV-6 encephalitis after allogeneic stem cell transplantation.
Eur Neurol 2005;2005
Soepenbergh O, Cornelissen JJ.
Behandeling met monoklonale antilichamen bij lymfoproliferatieve aandoeningen na transplantatie.
In: Immunotherapie van hematologische ziekten.
Van Zuiden Communications BV, Alphen aan den Rijn, 2005, pp 79-84.
Onder redactie van Prof. Dr. G.J. Ossenkoppele en Dr. A.A. van de Loosdrecht.
Cornelissen JJ.
Editorial commentaar bij het overzichtsartikel Kosteneffectiviteit van de behandeling van chronische myeloïde leukemie in het imatinibtijdperk van Groot et al.
Nederlands Tijdschrift voor Hematologie;2006:3:90-1.
- CURRICULUM VITAE -
28
Samijn JP, te Boekhorst PA, Mondria T, van Doorn PA, Flach HZ, van der Meché FG, Cornelissen J, Hop WC, Löwenberg B, Hintzen RQ.
Intense T cell depletion followed by autologous bone marrow transplantation for severe multiple sclerosis.
J Neurol Neurosurg Psychiatry 2006;77:46-50.
Görzer I, Niesters HGM, Cornelissen JJ, Puchhammer-Stöckl E.
Characterization of Epstein-Barr virus Type I variants based on linked polymorphism among EBNA3A, -3B, and -3C genes.
Virus Res 2006, 118:105-114.
Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gribben JH, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA; IRIS Investigators.
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
N Eng J Med 2006;355:2408-2417.
Cornelissen, Jan J. Abstract en Concreet.
Oratiereeks Erasmus Medisch Centrum, 1 september 2006.
ISBN 90-77906-32-2.
Harder H, Duivenvoorden HJ, van Gool AR, Cornelissen JJ, van den Bent MJ.
Neurocognitive functions and quality of life in haematological patients receiving haematopoietic stem cell grafts: a one-year follow-up pilot study.
J Clin Exp Neuropsychol 2006;28:283-293.
Te Boekhorst PA, Lamers CH, Schipperus MR, Hintzen RQ, van der Holt B, Cornelissen JJ, Löwenberg B, Gratama JW.
T-lymphocyte reconstitution following rigorously T-cell-depleted versus unmodified autologous stem

cell transplants.

Bone Marrow Transplant 2006;37:763-772.

Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shephard J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA, IRIS investigators.

Five-year follow-up of patients receiving imatinib for chronic myeloid leukaemia.

N Engl J Med. 2006;355:2408-17.

Deenik W, van der Holt B, Verhoef GE, Schattenberg AV, Verdonck LF, Daenen SM, Zachee P, Westveer PH, Smit WM, Wittebol S, Schouten HC, Löwenberg B, Ossenkoppele GJ, Cornelissen JJ. High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study.

Ann Hematol 2007;86:117-125 (E-pub 2006, Oct 10).

- CURRICULUM VITAE -

29

Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM, van Marwijk Kooy M, Wijermans P, Schouten H, Huijgens PC, van der Lelie H, Fey M, Ferrant A, Maertens J, Gratwohl A, Löwenberg B.

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

Blood 2007;109:3658-66.

Görzer I, Puchhammer-Stockl E, van Esser JW, Niesters HG, Cornelissen JJ.

Associations among Epstein-Barr virus subtypes, human leukocyte antigen class I alleles, and the development of posttransplantation lymphoproliferative disorder in bone marrow transplant recipients.

Clin Infect Dis 2007;44:693-5 (E-pub 2007, Jan 24).

Wils EJ, Braakman E, Verjans GM, Rombouts EJ, Broers AE, Niesters HG, Wagemaker G, Staal FJ, Lowenberg B, Spits H, Cornelissen JJ.

Flt3 ligand expands lymphoid progenitors prior to recovery of thymopoiesis and accelerates T cell reconstitution after bone marrow transplantation.

J Immunol. 2007;178:3551-7.

Van Hest RM, Doorduyn JK, de Winter BC, Cornelissen JJ, Vulto AG, Oellerich M, Lowenberg B, Mathot RA, Armstrong VW, van Gelder T.

Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients.

Ther Drug Monit. 2007;29:353-60.

Sonneveld P, van der Holt B, Segeren CM, Vellenga E, Croockewit AJ, Verhoe GE, Cornelissen JJ, Schaafsma MR, van Oers MH, Wijermans PW, Westveer PH, Lokhorst HM; Dutch-Belgian Hamto-Oncology Cooperatieve Group (HOVON).

Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial

Haematologica. 2007;92:928-35.

Heemskerk MB, Cornelissen JJ, Roelen DL, van Rood JJ, Claas FH, Doxiadis II, Oudshoorn M.

Highly diverged MHC class I mismatches are acceptable for haematopoietic stem cell transplantation.

Bone Marrow Transplant. 2007;40:193-200.

Agteresch HJ, van t Veer MB, Cornelissen JJ, Sluiter JF.

Visceral leishmaniasis after allogeneic hematopoietic stem cell transplantation.

Bone Marrow Transplant. 2007;40:391-3.

Harder H, Van Gool AR, Duivenoorden HJ, Cornelissen JJ, Eijkenboom WM, Barge RM, van den Bent MJ.

Case-referent comparison of cognitive functions in patients receiving haematopoietic stem-cell

transplantation for haematological malignancies Two-year follow-up results.

Eur J Cancer. 2007;43:2052-9.

Broers AE, Bruinsma M, Posthumus-van Sluijs SJ, Wils EJ, Spits H, Lowenberg B, Braakman E, Cornelissen JJ.

IL-7 mediated protection against minor antigen-mismatched allograft rejection is associated with enhanced recovery of regulatory T cells.

Haematologica. 2007;92:1099-106.

- CURRICULUM VITAE -

30

Malkki M, Gooley TA, Horowitz MM, Absi L, Christiansen FT, Cornelissen JJ, Dormoy A, Dubois V, Gagne K, Gluckman E, Haagenson MD, Oudshoorn M, Spellman S, Petersdorf EW; International Histocompatibility Working Group in Transplantation Mapping MHC-resident transplantation determinants.

Biology of Blood Marrow Transplantation. 2007;13:986-95.

Bruinsma M, Soest PL van, Leenen PJ, Lambrechts BN, Cupedo T, Löwenberg B, Cornelissen JJ, Braakman E.

Keratinocyte growth factor induces expansion of murine peripheral CD4+Foxp3+Regulatory T cells and increases their thymic output.

J Immunol. 2007;179:7424-30.

Cornelissen JJ.

Allogeneic stem cell transplantation in AML.

Nederlands Tijdschrift voor Hematologie. 2007;4:4-8.

Deenik W, Cornelissen JJ.

Resistentie tegen imatinib bij de behandeling van chronische myeloïde leukemie: mechanismen, het belang van adequate responsmonitoring en behandelingsmogelijkheden.

Nederlands Tijdschrift voor Hematologie. 2007;1:7-16.

Ossenkoppele GJ, Cornelissen JJ.

HOVON 78:prospectief gerandomiseerd onderzoek naar de combinatie van imatinib en cytarabine in vergelijking met imatinib alleen.

Nederlands Tijdschrift voor Hematologie. 2007;2:70-1.

Willemze R, Cornelissen JJ, Daenen SM, Dekker AW, Muus P.

Alemtuzumab voor volwassenen met een eerste of tweede recidief van acute lymfatische leukemie (HOVON 74).

Nederlands Tijdschrift voor Hematologie. 2007;5:190-1.

Brooimans RA, Kraan J, van Putten W, Cornelissen JJ, Löwenberg B, Gratama JW.

Flow cytometric differential of leukocyte populations in normal bone marrow: Influence of peripheral blood contamination¹.

Cytometry B Clin Cytom. 2008;76B:18-26.

Cornelissen JJ.

Mother and child reunion.

Blood. 2008;112:2604-5.

Deenik W, van der Holt B, Verhoef GE, Smit WM, Kersten MJ, Kluin-Nelemans HC, Verdonck LF, Ferrant A, Schattenberg AV, Janssen JJ, Sonneveld P, van Marwijk Kooy M, Wittebol S, Willemze R, Wijermans PW, Westveer PH, Beverloo HB, Valk P, Löwenberg B, Ossenkoppele GJ, Cornelissen JJ.

Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia.

Blood. 2008;111:2581-8.

- CURRICULUM VITAE -

31

Gratama JW, Brooimans RA, van der Holt B, Sintnicolaas K, van Doornum G, Niesters HG, Löwenberg B, Cornelissen JJ.

Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after

allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations.
Cytometry B Clin Cytom. 2008;74:211-20.

van Hest RM, Schnog JB, Vant Veer MB, Cornelissen JJ.
Extremely slow methotrexate elimination in a patient with t(9;22) positive acute lymphoblastic leukemia treated with imatinib.
Am J Hematol. 2008;83:757-8.

van Kempen-Harteveld ML, Brand R, Kal HB, Verdonck LF, Hofman P, Schattenberg AV, van der Maazen RW, Cornelissen JJ, Eijkenboom WM, van der Lelie JP, Oldenburger F, Barge RM, van Biezen A, Vossen JM, Noordijk EM, Struikmans H.
Results of hematopoietic stem cell transplantation after treatment with different high-dose total-body irradiation regimens in five Dutch centers.
Int J Radiat Oncol Biol Phys. 2008;71:1444-54.

Lodewyck T, Cornelissen JJ.
Allogeneic stem cell transplantation in acute myeloid leukemia: a risk-adapted approach.
Blood Rev. 2008;22:293-302.

Meijer E, Cornelissen JJ.
Allogeneic stem cell transplantation in acute myeloid leukemia in first or subsequent remission: weighing prognostic markers predicting relapse and risk factors for non-relapse mortality.
Semin Oncol. 2008;35:449-57.

Meijer E, Cornelissen JJ.
Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.
Curr Opin Hematol. 2008;15:576-85.

Rijnders BJ, Cornelissen JJ, Slobbe L, Becker MJ, Doorduijn JK, Hop WC, Ruijgrok EJ, Löwenberg B, Vulto A, Lugtenburg PJ, de Marie S.
Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial.
Clin Infect Dis. 2008;46:1401-8.

Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D, Hunter AE, Kanz L, Slavin S, Cornelissen JJ, Gramatzki M, Niederwieser D, Russell NH, Schmitz N.
Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkins lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
J Clin Oncol. 2008;26:455-62.

Bruinsma M, van Soest PL, Leenen PJ, Löwenberg B, Cornelissen JJ, Braakman E.
Keratinocyte growth factor improves allogeneic bone marrow engraftment through a CD4+Foxp3+ regulatory T cell-dependent mechanism.
J Immunol. 2009;182:7364-9.

- CURRICULUM VITAE -

32

Cornelissen JJ, van der Holt B, Verhoef GE, van t Veer MB, van Oers MH, Schouten HC, Ossenkoppele G, Sonneveld P, Maertens J, van Marwijk Kooy M, Schaafsma MR, Wijermans PW, Biesma DH, Wittebol S, Voogt PJ, Baars JW, Zachee P, Verdonck LF, Lowenberg B, Dekker AW.
Dutch-Belgian HOVON Cooperative Group.
Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison.
Blood. 2009;113:1375-82.

Cupedo T, Crellin NK, Papazian N, Rombouts EJ, Weijer K, Grogan JL, Fibbe WE, Cornelissen JJ, Spits H.
Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells.
Nat Immunol. 2009;10:66-74.

Deenik W, Beverloo HB, van der Poel-van de Luytgaarde SC, Wattel MM, van Esser JW, Valk PJ,

Cornelissen JJ.

Rapid complete cytogenetic remission after upfront dasatinib monotherapy in a patient with a NUP214-ABL1-positive T-cell acute lymphoblastic leukemia.

Leukemia, 2009;23:627-9.

Holler E, Kolb HJ, Greinix H, Perrotin D, Campilho F, Aversa F, Gil L, Cornelissen JJ, Varanese L, Schacht A, Friese A, Rustige J.

Bleeding events and mortality in SCT patients: a retrospective study of hematopoietic SCT patients with organ dysfunctions due to severe sepsis or GVHD.

Bone Marrow Transplant 2009;43:491-7.

Lodewyck, Cornelissen JJ.

Wikken en wegen: wat is de plaats van de allogene stamceltransplantatie bij volwassen patiënten met acute myeloïde leukemie in eerste complete remissie?

Nederlands Tijdschrift voor Hematologie 2009;1:3-9.

Schattenberg AV, Schouten HC, Verdonck LF, Willemze R, van der Lelie J, Huijgens PC, van Imhoff GW, van Biezen A, Brand R, Hagenbeek A, de Witte T, Cornelissen JJ.

Allogenic stem cell transplantation in the Netherlands.

Ned Tijdschr Geneesk 2009;153:380-5.

Vroegindewij E, Crobach S, Itoi M, Sathoh R, Zuklys S, Happe C, Germeraad WT, Cornelissen JJ, Cupedo T, Hollander GA, Kawamoto H, van Ewijk W.

Thymic cysts originate from Foxn1 positive thymic medullary epithelium

Mol Immunol 2010;47:1106-13

Deenik W, Van der Holt B, Janssen JJ, Chu IW, Valk PJ, Ossenkuppele GJ, Van der Heiden IP, Sonneveld P, Van Schaik RH, Cornelissen JJ.

Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib.

Blood 2010;116:6144-45

Kyriakou C, Canals C, Cornelissen JJ, Socié G, Willemze R, Ifrah N, Greinix HT, Blaise D, Deconinck E, Ferrant A, Schattenberg A, Harousseau JL, Sureda A, Schmitz N.

Allogeneic stem cell transplantation in patients with Waldenström macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

J Clin Oncol 2010;28:4926-34

- CURRICULUM VITAE -

33

Bruinsma M, Wils EJ, Löwenberg B, Cornelissen JJ, Braakman E.

The impact of CD4+Foxp3+ Treg on immunity to murine cytomegalovirus after bone marrow transplantation depends on the peripheral or thymic source of T cell regeneration.

Transpl Immunol 2010;24:9-16

Gratama JW, Boeckh M, Nakamura R, Cornelissen JJ, Brooimans RA, Zaia JA, Forman SJ, Gaal K, Bray KR, Gasior GH, Boyce CS, Sullivan LA, Southwick PC.

Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study.

Blood 2010;116:1655-62

Janssen JJ, Denkers F, Valk P, Cornelissen JJ, Schuurhuis GJ, Ossenkuppele GJ.

Methylation patterns in CD34 positive chronic myeloid leukemia blast crisis cells.

Haematologica 2010; 95:1036-7

Deenik W, Janssen JJ, Van der Holt B, Verhoef GE, Smit WM, Kersten MJ, Daenen SM, Verdonck LF, Ferrant A, Schattenberg AV, Sonneveld P, Van Marwijk Kooy M, Wittebol S, Willemze R, Wijermans PW, Beverloo HB, Löwenberg B, Valk PJ, Ossenkuppele GJ, Cornelissen JJ.

Haematologica 2010;95:914-21

Ljungman P, Bregni M, Brune M, Cornelissen JJ, Witte TD, Dini G, Einsele H, Gaspar HB, Gratwohl A, Passweg J, Peters C, Rocha V, Saccardi R, Schouten H, Sureda A, Tichelli A, Velardi A, Niederwieser D.

Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009.
 Bone Marrow Transplant 2010;45:219-34

Ossenkoppele GJ, Janssen JJWM, Posthuma EFM, Bos GMJ, Petersen EJ, Schattenberg AVMB, Verhoef GEG, Vellenga E, Cornelissen JJ.
 Aanbevelingen voor de behandeling van chronische myeloïde leukemie namens de HOVON Leukemie Werkgroep.
 Nederlands Tijdschrift voor Hematologie 2010;5:198-206

Petzold A, Mondria T, Kuhle J, Rocca MA, Cornelissen JJ, Te Boekhorst P, Löwenberg B, Giovannoni G, Filippi M, Kappos L, Hintzen R.
 Evidence for acute neurotoxicity after chemotherapy.
 Ann Neurol 2010;68:806-15

Lodewyck T, Oudshoorn M, Van der Holt B, Petersen E, Spierings E, Von dem Borne PA, Schattenberg A, Allebes W, Groenendijk-Sijnke M, Duinhouwer L, Willemze R, Löwenberg B, Verdonck LF, Meijer E, Cornelissen JJ,
 Predictive impact of allele matching and EBMT risk score for outcome after T-cell depleted unrelated donor transplantation in poor-risk acute leukemia and myelodysplasia
 Leukemia. 2011;25:1548-54

Gratwohl A, Brand R, Niederwieser D, Baldomero H, Chabannon C, Cornelissen J, de Witte T, Ljungman P, McDonald F, McGrath E, Passweg J, Peters C, Rocha V, Slaper-Cortenbach I, Sureda A, Tichelli A, Apperley J
 Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation
 J Clin Oncol. 2011;29:1980-6

- CURRICULUM VITAE -
 34

Chevallier P, Labopin M, Cornelissen J, Socié G, Rocha V, Mohty M
 Allogeneic hematopoietic stem cell transplantation for isolated and leukemic myeloid sarcoma in adults: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation
 Haematologica 2011;96:1391-1394

Kneppers E, van der Holt B, Kersten MJ, Zweegman S, Meijer E, Huls G, Cornelissen JJ, Janssen JJ, Huisman C, Cornelisse PB, Bruijnen CP, Emmelot M, Sonneveld P, Lokhorst HM, Mutis T, Minnema MC
 Lenalidomide maintenance following non-myeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 trial
 Blood 2011;118:2413-2419

Wils EJ, Rombouts EJ, van Mourik I, Spits H, Legrand N, Braakman E, Cornelissen JJ
 Stem cell factor consistently improves thymopoiesis after experimental transplantation of murine or human hematopoietic stem cells in immunodeficient mice.
 J Immunol. 2011;187:2974-2981

Lodewyck T, Oudshoorn M, van der Holt B, Petersen E, Spierings E, von dem Borne PA, Schattenberg A, Allebes W, Groenendijk-Sijnke M, Duinhouwer L, Willemze R, Löwenberg B, Verdonck LF, Meijer E, Cornelissen JJ
 Predictive impact of allele-matching and EBMT risk score for outcome after T-cell depleted unrelated donor transplantation in poor-risk acute leukemia and myelodysplasia.
 Leukemia 2011;25:1548-1554

Rijneveld AW, van der Holt B, Daenen SM, Biemond BJ, de Weerd O, Muus P, Maertens J, Mattijssen V, Demuyneck H, Legdeur MC, Wijermans PW, Wittebol S, Spoelstra FM, Dekker AW, Ossenkoppele GJ, Willemze R, Cornelissen JJ
 Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40
 Leukemia 2011;25:1697-1703

Wils EJ, van der Holt B, Broers AE, Posthumus-van Sluijs SJ, Gratama JW, Braakman E, Cornelissen JJ

Insufficient recovery of thymopoiesis predicts for opportunistic infection in allogeneic hematopoietic stem cell transplantation recipients.

Haematologica 2011;96:1846-1854

Vellenga E, van Putten W, Ossenkoppele GJ, Verdonck LF, Theobald M, Cornelissen JJ, Huijgens PC, Maertens J, Gratwohl A, Schaafsma R, Schanz U, Graux C, Schouten HC, Ferrant A, Bargetzi M, Fey MF, Löwenberg B

Autologous peripheral blood stem cell transplantation for acute myeloid leukemia

Blood 2011;118:6037-6042

Janssen JJ, Deenik W, Smolders KG, van Kuijk BJ, Pouwels W, Kelder A, Cornelissen JJ, Schuurhuis GJ, Ossenkoppele GJ

Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib

Leukemia 2012;26::977-984

- CURRICULUM VITAE -

35

Wils EJ, Aerts-Kaya FS, Rombouts EJ, van Mourik I, Rijken-Schelen A, Visser TP, Braakman E, Wagemaker G, Cornelissen JJ

Keratinocyte Growth Factor and Stem Cell Factor to Improve Thymopoiesis after Autologous CD34(+) Cell Transplantation in Rhesus Macaques.

Biol Blood Marrow Transplant 2012;18:55-65

Cornelissen JJ, Breems D, van Putten WL, Gratwohl AA, Passweg JR, Pabst T, Maertens J, Beverloo HB, van Marwijk Kooy M, Wijermans PW, Biemond BJ, Vellenga E, Verdonck LF, Ossenkoppele GJ, Löwenberg B. Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. J Clin Oncol. 2012 Jun 10;30(17):2140-46.

Baron F, Labopin M, Niederwieser D, Vigouroux S, Cornelissen JJ, Malm C, Vindelov LL, Blaise D, Janssen JJ, Petersen E, Socié G, Nagler A, Rocha V, Mohty M. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia. 2012;26:2462-68

Nagler A, Labopin M, Shimoni A, Mufti GJ, Cornelissen JJ, Blaise D, Janssen JJ, Milpied N, Vindelov L, Petersen E, Gribben J, Bacigalupo A, Malm C, Niederwieser D, Socié GJ, Arnold R, Brown P, Goker H, Rocha V, Mohty M. Mobilized Peripheral Blood Stem Cells compared with bone marrow from HLA-identical siblings for reduced-intensity conditioning transplantation in acute myeloid leukemia in complete remission: a retrospective analysis from the Acute Leukemia Working Party of EBMT. Eur J Haematol. 2012;89:206-13

van Hensbergen Y, Mulder A, Cornelissen JJ, Brand A. Validation of human monoclonal HLA Class I antibodies to evaluate the kinetics of donor chimerism in different cell subsets after double-cord-blood transplantation in the NOD/SCID model. Transfusion. 2012;53:104-14

Chevallier P, Labopin M, Milpied N, Cornelissen JJ, Blaise D, Petersen E, Sandstedt A, Goker H, Socié G, Rocha V, Mohty M. Impact of cytogenetics risk on outcome after reduced intensity conditioning allo-SCT from an HLA-identical sibling for patients with AML in first CR: a report from the acute leukemia working party of EBMT. Bone Marrow Transplant. 2012;47:1441-47

Nagler A, Labopin M, Shimoni A, Niederwieser D, Mufti GJ, Zander AR, Arnold R, Greinix H, Cornelissen JJ, Jackson GH, Craddock C, Bunjes DW, Ganser A, Russell NH, Kyrz-Krzemien S, Rocha V, Mohty M. Mobilized Peripheral Blood Stem Cells Compared with Bone Marrow as the Stem Cell Source for Unrelated Donor Allogeneic Transplantation with Reduced-Intensity Conditioning in Patients with Acute Myeloid Leukemia in Complete Remission: An Analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18:1422-29

- CURRICULUM VITAE -

Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJ, van Oers M, Raymakers R, Minnema MC, Zweegman S, Janssen JJ, Zijlmans M, Bos G, Schaap N, Wittebol S, de Weerd O, Ammerlaan R, Sonneveld P. Donor versus no donor comparison of newly diagnosed myeloma patients included in the HOVON 50 multiple myeloma study. *Blood*. 2012;119:6219-25

Daenen S, van der Holt B, Dekker AW, Willemze R, Rijnveld AW, Biemond BJ, Muus P, van de Loosdrecht AA, Schouten HC, van Marwijk Kooy M, Breems DA, Demuyneck H, Maertens J, Wijermans PW, Wittebol S, de Klerk EW, Cornelissen JJ. Intensive chemotherapy to improve outcome in patients with acute lymphoblastic leukemia over the age of 40: a phase II study for efficacy and feasibility by HOVON. *Leukemia*. 2012;26:1726-1729

Brunet S, Labopin M, Esteve J, Cornelissen J, Socié G, Iori AP, Verdonck LF, Volin L, Gratwohl A, Sierra J, Mohty M, Rocha V. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. *J Clin Oncol*. 2012;30:735-41

Schmid C, Labopin M, Nagler A, Niederwieser D, Castagna L, Tabrizi R, Stadler M, Kuball J, Cornelissen J, Vorlicek J, Socié G, Falda M, Vindeløv L, Ljungman P, Jackson G, Kröger N, Rank A, Polge E, Rocha V, Mohty M; Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. *Blood*. 2012 Feb 9;119(6):1599-606

Janssen JJ, Deenik W, Smolders KG, van Kuijk BJ, Pouwels W, Kelder A, Cornelissen JJ, Schuurhuis GJ, Ossenkoppele GJ. Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib. *Leukemia*. 2012 May;26(5):977-84

Mounier N, Canals C, Gisselbrecht C, Cornelissen J, Foa R, Conde E, Maertens J, Attal M, Rambaldi A, Crawley C, Luan JJ, Brune M, Wittnebel S, Cook G, van Imhoff GW, Pfreundschuh M, Sureda A; for the Lymphoma Working Party of the European Blood and Marrow Transplantation Registry (EBMT). High-Dose Therapy and Autologous Stem Cell Transplantation in First Relapse for Diffuse Large B Cell Lymphoma in the Rituximab Era: An Analysis Based on Data from the European Blood and Marrow Transplantation Registry *Biol Blood Marrow Transplant*. 2012;18:788-93

Cornelissen J, Gratwohl A, Schlenk R, Sierra J, Bornhäuser M, Juliusson G, Ráčil Z, Rowe J, Russell N, Mohty M, Löwenberg B, Socié G, Niederwieser D, Ossenkoppele G.

The European LeukemiaNet AML Working Party consensus statement on allogeneic stem cell transplantation for patients with AML in remission: an integrated-risk adapted approach *Nat Rev Clin Oncol*. 2012;9:579-90

Blommestein HM, Verelst SG, Huijgens PC, Blijlevens NM, Cornelissen JJ, Uyl-de Groot CA. Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study

Ann Hematol. 2012;91:1945-52

- CURRICULUM VITAE -

Greijer AE, Stevens SJ, Verkuijlen SA, Juwana H, Fleig SC, Verschuuren EA, Hepkema BG, Cornelissen JJ, Brooimans RA, Verdonck LF, Middeldorp JM.

Variable EBV DNA load distributions and heterogeneous EBV mRNA expression patterns in the circulation of solid organ versus stem cell transplant recipients.

Clin Dev Immunol. 2012;2012:543085

Giebel S, Labopin M, Mohty M, Mufti GJ, Niederwieser D, Cornelissen JJ, Janssen JJ, Milpied N, Vindeløv L, Petersen E, Arnold R, Bacigalupo A, Blaise D, Craddock C, Nagler A, Frassoni F, Sados-Wojciechowska M, Rocha V.

The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT.

Bone Marrow Transplant. 2013;48:238-42

Somers JA, Brand A, van Hensbergen Y, Mulder A, Oudshoorn M, Sintnicolaas K, Gratama JW, Falkenburg JH, Braakman E, Cornelissen JJ.
Double umbilical cord blood transplantation: A study of early engraftment kinetics in leukocyte subsets using HLA-specific monoclonal antibodies.
Biol Blood Marrow Transplant. 2013;19:266-73

Roos-Weil D, Dietrich S, Boumendil A, Polge E, Bron D, Carreras E, Iriando Atienza A, Arcese W, Beelen DW, Cornelissen JJ, Kröger N, Milone G, Rossi G, Jardin F, Peters C, Rocha V, Suredea A, Mohty M, Dreger P; European Group for Blood and Marrow Transplantation Lymphoma, Pediatric Diseases, and Acute Leukemia Working Parties
Stem cell transplantation can provide durable disease control in blastic plasmacytoid dendritic cell neoplasm: a retrospective study from the European Group for Blood and Marrow Transplantation
Blood. 2013;121(3):440-46

Lauw MN, Van der Holt B, Middeldorp S, Meijers JC, Cornelissen JJ, Biemond BJ.
Venous thromboembolism in adults treated for acute lymphoblastic leukaemia: Effect of fresh frozen plasma supplementation.
Thromb Haemost. 2013 Apr;109(4):633-42.

Jöris MM, Lankester AC, von dem Borne PA, Kuball J, Bierings M, Cornelissen JJ, Groenendijk-Sijne ME, van der Holt B, Haasnoot GW, van der Zanden HG, van Walraven SM, van Rood JJ, Claas FH, Oudshoorn M.
The impact of frequent HLA haplotypes in high linkage disequilibrium on donor search and clinical outcome after unrelated haematopoietic SCT.
Bone Marrow Transplant. 2013 Apr;48(4):483-90.

Farley AM, Morris LX, Vroegindewij E, Depreter ML, Vaidya H, Stenhouse FH, Tomlinson SR, Anderson RA, Cupedo T, Cornelissen JJ, Blackburn CC.
Dynamics of thymus organogenesis and colonization in early human development.
Development. 2013 May;140(9):2015-26.

Vroegindewij E, van Mourik I, Cupedo T, Cornelissen JJ.
Characterization of Lgr5-positive epithelial cells in the murine thymus.
Eur J Immunol. 2013 May;43(5):1243-51.

Versluis J, Pas SD, Agteresch HJ, de Man RA, Maaskant J, Schipper ME, Osterhaus AD, Cornelissen JJ, van der Eijk AA.
Hepatitis E virus: an underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation.
Blood. 2013 Aug 8;122(6):1079-86.

- CURRICULUM VITAE -
38

Thielen N, van der Holt B, Verhoef GE, Ammerlaan RA, Sonneveld P, Janssen JJ, Deenik W, Falkenburg JH, Kersten MJ, Sinnige HA, Schipperus M, Schattenberg A, van Marwijk Kooy R, Smit WM, Chu IW, Valk PJ, Ossenkoppele GJ, Cornelissen JJ.
High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.
Ann Hematol. 2013 Aug;92(8):1049-56.

Schlenk RF, Taskesen E, van Norden Y, Krauter J, Ganser A, Bullinger L, Gaidzik VI, Paschka P, Corbacioglu A, Göhring G, Kündgen A, Held G, Götze K, Vellenga E, Kuball J, Schanz U, Passweg J, Pabst T, Maertens J, Ossenkoppele GJ, Delwel R, Döhner H, Cornelissen JJ, Döhner K, Löwenberg B.
The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA.
Blood. 2013 Aug 29;122(9):1576-82.
Cornelissen JJ.
Old wine in a new bottle: ready to drink?
Blood. 2013 Sep 5;122(10):1689-90.

Thielen N, van der Holt B, Cornelissen JJ, Verhoef GE, Gussinklo T, Biemond BJ, Daenen SM, Deenik W, van Marwijk Kooy R, Petersen E, Smit WM, Valk PJ, Ossenkuppele GJ, Janssen JJ. Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON).

Eur J Cancer. 2013 Oct;49(15):3242-6.

de Pagter PJ, Schuurman R, Keukens L, Schutten M, Cornelissen JJ, van Baarle D, Fries E, Sanders EA, Minnema MC, van der Holt BR, Meijer E, Boelens JJ.

Human herpes virus 6 reactivation: important predictor for poor outcome after myeloablative, but not non-myeloablative allo-SCT.

Bone Marrow Transplant. 2013 Nov;48(11):1460-4.

Rodrigues CA, Rocha V, Dreger P, Brunstein CG, Sengeloiev H, Finke J, Mohty M, Rio B, Petersen E, Guilhot F, Niederwieser D, Cornelissen JJ, Jindra P, Nagler A, Fegueux N, Schoemans H, Robinson S, Ruggeri A, Gluckman E, Canals C, Sureda A.

Alternative donor hematopoietic stem cell transplantation for mature lymphoid malignancies after reduced-intensity conditioning regimen: similar outcomes with umbilical cord blood and unrelated donor peripheral blood.

Haematologica. 2013 Aug 9. [Epub ahead of print]doi:10.3324/haematol.2013.088997

Dietrich S, Boumendil A, Finel H, Avivi I, Volin L, Cornelissen J, Jarosinska RJ, Schmid C, Finke J, Stevens WB, Schouten HC, Kaufmann M, Sebban C, Trnety M, Kobbe G, Fornecker LM, Schetelig J, Kanfer E, Heinicke T, Pfreundschuh M, Diez-Martin JL, Bordessoule D, Robinson S, Dreger P. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem cell transplantation: A retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).

Ann Oncol. 2014 Feb 27. [Epub ahead of print]

- CURRICULUM VITAE -

39

Middeke JM, Fang M, Cornelissen JJ, Mohr B, Appelbaum FR, Stadler M, Sanz J, Baurmann H, Bug G, Schäfer-Eckart K, Hegenbart U, Bochtler T, Röllig C, Stölzel F, Walter RB, Ehninger G, Bornhäuser M, Löwenberg B, Schetelig J.

Outcome of patients with abnl (17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

Blood. 2013 Mar 20. [Epub ahead of print]

Yeshurun M, Labopin M, Blaise D, Cornelissen JJ, Sengeloiev H, Vindelov L, Kuball J, Chevallier P, Craddock C, Socie G, Bilger K, Schouten HC, Fegueux N, Goker H, Maertens J, Bunjes D, Arnold R, Nagler A, Mohty M.

Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: A report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Cancer. 2014 Mar;120(6):855-63

Jöris MM, Lankester AC, von dem Borne PA, Kuball J, Bierings M, Cornelissen JJ, Sijnke ME, van der Holt B, van Rood JJ, Oudshoorn M, Claas FH.

Translating in vitro prediction of cytotoxic T cell alloreactivity to hematopoietic stem cell transplantation outcome.

Transpl Immunol. 2014 Mar;30 (2-3):59-64

Dietrich S, Boumendil A, Finel H, Avivi I, Volin L, Cornelissen J, Jarosinska RJ, Schmid C, Finke J, Stevens WB, Schouten HC, Kaufmann M, Sebban C, Trnety M, Kobbe G, Fornecker LM, Schetelig J, Kanfer E, Heinicke T, Pfreundschuh M, Diez-Martin JL, Bordessoule D, Robinson S, Dreger P. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT).

Ann Oncol. 2014 May;25(5):1053-8.

Middeke JM, Fang M, Cornelissen JJ, Mohr B, Appelbaum FR, Stadler M, Sanz J, Baumann H, Bug G, Schäfer-Eckart K, Hegenbart U, Bochtler T, Röllig C, Stölzel F, Walter RB, Ehninger G, Bornhäuser M, Löwenberg B, Schetelig J.

Outcome of patients with abn(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

Blood. 2014 May 8;123(19):2960-7. doi: 10.1182/blood-2013-12-544957.

Tucunduva L, Ruggeri A, Sanz G, Furst S, Socié G, Michallet M, Arcese W, Milpied N, Yakoub-Agha I, Linkesch W, Cornelissen J, Mannone L, Iori AP, Ribera JM, Sanz J, Montesinos P, Purtill D, Labopin M, Gluckman E, Mohty M, Rocha V.

Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Bone Marrow Transplant. 2014 Jul;49(7):887-94.

van der Eijk AA, Pas SD, Cornelissen JJ, de Man RA.

Hepatitis E virus infection in hematopoietic stem cell transplant recipients.

Curr Opin Infect Dis. 2014 Aug;27(4):309-15.

- CURRICULUM VITAE -

40

Tucunduva L, Ruggeri A, Sanz G, Furst S, Cornelissen J, Linkesch W, Mannone L, Ribera JM, Veelken H, Yakoub-Agha I, González Valentín ME, Schots R, Arcese W, Montesinos P, Labopin M, Gluckman E, Mohty M, Rocha V.

Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of the European group for Blood and Marrow Transplantation.

Br J Haematol. 2014 Sep;166(5):749-57.

Somers JA, Braakman E, van der Holt B, Petersen EJ, Marijt EW, Huisman C, Sintnicolaas K, Oudshoorn M, Groenendijk-Sijne ME, Brand A, Cornelissen JJ.

Rapid induction of single donor chimerism after double umbilical cord blood transplantation preceded by reduced intensity conditioning: results of the HOVON 106 phase II study.

Haematologica. 2014 Nov;99(11):1753-61.

Versluis J, Labopin M, Niederwieser D, Socie G, Schlenk RF, Milpied N, Nagler A, Blaise D, Rocha V, Cornelissen JJ, Mohty M.

Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission.

Leukemia. 2015 Jan;29(1):51-7.

Eder S, Labopin M, Arcese W, Or R, Majolino I, Bacigalupo A, de Rosa G, Volin L, Beelen D, Veelken H, Schaap NP, Kuball J, Cornelissen J, Nagler A, Mohty M.

Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Acute Leukemia Working Party. Eur J Haematol. 2015 Mar 21. doi: 10.1111/ejh.12553.

Duinhouwer LE, Tüysüz N, Rombouts EW, Ter Borg MN, Mastrobattista E, Spanholtz J, Cornelissen JJ, Ten Berge D, Braakman E.

Wnt3a protein reduces growth factor-driven expansion of human hematopoietic stem and progenitor cells in serum-free cultures.

PLoS One. 2015 Mar 25;10(3):e0119086. doi: 10.1371/journal.pone.0119086. eCollection 2015.

Koenecke C, Göhring G, de Wreede LC, van Biezen A, Scheid C, Volin L, Maertens J, Finke J, Schaap N, Robin M, Passweg J, Cornelissen J, Beelen D, Heuser M, de Witte T, Kröger N

Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective

multicenter study of the European Society of Blood and Marrow Transplantation.
MDS subcommittee of the Chronic Malignancies Working Party of the EBMT.

Haematologica. 2015 Mar;100(3):400-8.

Brissot E, Labopin M, Beckers MM, Socié G, Rambaldi A, Volin L, Finke J, Lenhoff S, Kröger N, Ossenkoppele GJ, Craddock CF, Yakoub-Agha I, Gürman G, Russell NH, Aljurf M, Potter MN, Nagler A, Ottmann O, Cornelissen JJ, Esteve J, Mohty M.

Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.

Haematologica. 2015 Mar;100(3):392-9.

- CURRICULUM VITAE -

41

Cornelissen JJ, Versluis J, Passweg JR, van Putten WL, Manz MG, Maertens J, Beverloo HB, Valk PJ, van Marwijk Kooy M, Wijermans PW, Schaafsma MR, Biemond BJ, Vekemans MC, Breems DA, Verdonck LF, Fey MF, Jongen-Lavrencic M, Janssen JJ, Huls G, Kuball J, Pabst T, Graux C, Schouten HC, Gratwohl A, Vellenga E, Ossenkoppele G, Löwenberg B.

Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years. HOVON; SAKK Leukemia Groups.

Leukemia. 2015 May;29(5):1041-50.

Beije N, Versluis J, Kraan J, Gratama JW, Sleijfer S, Cornelissen JJ.

Circulating endothelial cell enumeration demonstrates prolonged endothelial damage in recipients of myeloablative allogeneic stem cell transplantation.

Haematologica. 2015 Jun;100(6):e246-9.

Morris C, Iacobelli S, Gahrton G, van Biezen A, Drake M, Garderet L, Potter M, Schattenberg AV, Cornelissen JJ, Hamladji RM, Martelli M, Petersen E, Rovira M, Bandini G, Kroger N, de Witte T.

Efficacy and outcome of allogeneic transplantation in IgD and nonsecretory myeloma. A report on behalf of the Myeloma Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.

Biol Blood Marrow Transplant. 2015 Jun;21(6):1054-8.

Symeonidis A, van Biezen A, de Wreede L, Piciocchi A, Finke J, Beelen D, Bornhäuser M, Cornelissen J, Volin L, Mufti G, Chalandon Y, Ganser A, Bruno B, Niederwieser D, Kobbe G, Schwerdtfeger R, de Witte T, Robin M, Kröger N.

Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.

Br J Haematol. 2015 Jul 26. doi: 10.1111/bjh.13576.

Zuurbier SM, Lauw MN, Coutinho JM, Majoie CB, van der Holt B, Cornelissen JJ, Middeldorp S, Biemond BJ, Stam J.

Clinical Course of Cerebral Venous Thrombosis in Adult Acute Lymphoblastic Leukemia.

J Stroke Cerebrovasc Dis. 2015 Jul;24(7):1679-84. doi: 10.1016/j.jstrokecerebrovasdis.2015.03.041.

Boer JM, Koenders JE, van der Holt B, Exalto C, Sanders MA, Cornelissen JJ, Valk PJ, den Boer ML, Rijnveld AW.

Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates.

Haematologica. 2015 Jul;100(7):e261-4. doi: 10.3324/haematol.2014.117424. Epub 2015 Mar 13.

Chong GL, Broekman F, Polinder S, Doorduijn JK, Lugtenburg PJ, Verbon A, Cornelissen JJ, Rijnders BJ.

Aerosolised liposomal amphotericin B to prevent aspergillosis in acute myeloid leukaemia: Efficacy and cost effectiveness in real-life.

Int J Antimicrob Agents. 2015 Jul;46(1):82-7. doi: 10.1016/j.ijantimicag.2015.02.023.

Pascal L, Tucunduva L, Ruggeri A, Blaise D, Ceballos P, Chevallier P, Cornelissen J, Maillard N, Tabrizi R, Petersen E, Linkesch W, Sengeloef H, Kenzey C, Pagliuca A, Holler E, Einsele H,

Gluckman E, Rocha V, Yakoub-Agha I.

Impact of ATG-containing reduced-intensity conditioning after single- or double-unit allogeneic cord blood transplantation. Eurocord and the European Society for Blood and Marrow Transplantation. *Blood*. 2015 Aug 20;126(8):1027-32. doi: 10.1182/blood-2014-09-599241.

- CURRICULUM VITAE -

42

Passweg JR, Labopin M, Cornelissen J, Volin L, Socié G, Huynh A, Tabrizi R, Wu D, Craddock C, Schaap N, Kuball J, Chevallier P, Cahn JY, Blaise D, Ghavamzadeh A, Bilger K, Ciceri F, Schmid C, Giebel S, Nagler A, Mohty M.

Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT. Acute Leukemia Working Party of the European Blood and Marrow Transplant Group (EBMT).

Bone Marrow Transplant. 2015 Aug;50(8):1063-8. doi: 10.1038/bmt.2015.121.

Poiré X, Labopin M, Cornelissen JJ, Volin L, Richard Espiga C, Veelken JH, Milpied N, Cahn JY, Yakoub-Agha I, van Imhoff GW, Michallet M, Michaux L, Nagler A, Mohty M.

Outcome of conditioning intensity in acute myeloid leukemia with monosomal karyotype in patients over 45 year-old: A study from the acute leukemia working party (ALWP) of the European group of blood and marrow transplantation (EBMT).

Am J Hematol. 2015 Aug;90(8):719-24.

Xavier E, Cornillon J, Ruggeri A, Chevallier P, Cornelissen JJ, Andersen NS, Maillard N, Nguyen S, Blaise D, Deconinck E, Veelken H, Milpied N, Van Gelder M, Peffault de Latour R, Gluckman E, Kröger N, Schetelig J, Rocha V.

Outcomes of Cord Blood Transplantation Using Reduced-Intensity Conditioning for Chronic Lymphocytic Leukemia: A Study on Behalf of Eurocord and Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation, and the Société Française de Greffe de Moelle et Therapie Cellulaire.

Biol Blood Marrow Transplant. 2015 Aug;21(8):1515-23. doi: 10.1016/j.bbmt.2015.04.026.

Duinhouwer LE, van Rossum BJ, van Tiel ST, van der Werf RM, Doeswijk GN, Haeck JC, Rombouts EW, Ter Borg MN, Kotek G, Braakman E, Cornelissen JJ, Bernsen MR.

Magnetic Resonance Detection of CD34+ Cells from Umbilical Cord Blood Using a 19F Label.

PLoS One. 2015 Sep 22;10(9):e0138572. doi: 10.1371/journal.pone.0138572. eCollection 2015.

Versluis J, Hazenberg CL, Passweg JR, van Putten WL, Maertens J, Biemond BJ, Theobald M, Graux C, Kuball J, Schouten HC, Pabst T, Löwenberg B, Ossenkoppele G, Vellenga E, Cornelissen JJ.

Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis. HOVON and SAKK Leukemia Groups.

Lancet Haematol. 2015 Oct;2(10):e427-36.

Shouval R, Labopin M, Bondi O, Mishan-Shamay H, Shimoni A, Ciceri F, Esteve J, Giebel S, Gorin NC, Schmid C, Polge E, Aljurf M, Kroger N, Craddock C, Bacigalupo A, Cornelissen JJ, Baron F, Unger R, Nagler A, Mohty M.

Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study.

J Clin Oncol. 2015 Oct 1;33(28):3144-51. doi: 10.1200/JCO.2014.59.1339. Epub 2015 Aug 3.

Penack O, Tridello G, Hoek J, Socié G, Blaise D, Passweg J, Chevallier P, Craddock C, Milpied N, Veelken H, Maertens J, Ljungman P, Cornelissen J, Thiebaut-Bertrand A, Lioure B, Michallet M, Iacobelli S, Nagler A, Mohty M, Cesaro S.

Influence of pre-existing invasive aspergillosis on allo-HSCT outcome: a retrospective EBMT analysis by the Infectious Diseases and Acute Leukemia Working Parties.

Bone Marrow Transplant. 2015 Oct 26. doi: 10.1038/bmt.2015.237.

- CURRICULUM VITAE -

43

Schmid C, Labopin M, Socié G, Daguindau E, Volin L, Huynh A, Bourhis JH, Milpied N, Cornelissen J, Chevallier P, Maertens J, Jindra P, Blaise D, Lenhoff S, Ifrah N, Baron F, Ciceri F, Gorin C, Savani B, Giebel S, Polge E, Esteve J, Nagler A, Mohty M.

Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. Acute Leukemia Working Party of the European Group of Blood and Bone Marrow Transplantation.

Blood. 2015 Oct 22;126(17):2062-9. doi: 10.1182/blood-2015-06-651562. Epub 2015 Sep 8.

Peffault de Latour R, Labopin M, Cornelissen J, Vigouroux S, Craddock C, Blaise D, Huynh A, Vindelov L, Maertens J, Chevallier P, Fegueux N, Socié G, Cahn JY, Petersen E, Schouten H, Lioure B, Russell N, Corral LL, Ciceri F, Nagler A, Mohty.

In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available?

M. Bone Marrow Transplant. 2015 Nov;50(11):1411-5. doi: 10.1038/bmt.2015.180. Epub 2015 Sep 14.

Lokhorst HM, van der Holt B, Cornelissen JJ, Kersten MJ, van Oers M, Raymakers R, Minnema MC, Zweegman S, Bos G, Schaap N, Wittebol S, de Weerd O, Ammerlaan R, Sonneveld P.

Reduced relapse rate in upfront tandem autologous/reduced-intensity allogeneic transplantation in multiple myeloma only results in borderline non-significant prolongation of progression-free but not overall survival.

Haematologica. 2015 Dec;100(12):e508-10. doi: 10.3324/haematol.2015.128728. Epub 2015 Sep 4.

Chong GM, Maertens JA, Lagrou K, Driessen GJ, Cornelissen JJ, Rijnders BJ.

Diagnostic performance of galactomannan antigen testing in cerebrospinal fluid.

J Clin Microbiol. 2015 Dec 9. pii: JCM.02913-15.

Dinmohamed AG, Visser O, van Norden Y, Blijlevens NM, Cornelissen JJ, Huls GA, Huijgens PC, Sonneveld P, van de Loosdrecht AA, Ossenkoppele GJ, Löwenberg B, Jongen-Lavrencic M.

Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989-2012.

Leukemia. 2016 Jan;30(1):24-31. doi: 10.1038/leu.2015.188. Epub 2015 Jul 17.

Nijskens CM, Pas SD, Cornelissen JJ, Caliskan K, Hoek RA, Hesselink DA, van der Eijk AA, de Man RA.

Hepatitis E virus genotype 3 infection in a tertiary referral center in the Netherlands: Clinical relevance and impact on patient morbidity.

J Clin Virol. 2016 Jan;74:82-7. doi: 10.1016/j.jcv.2015.11.038. Epub 2015 Dec 2.

Cornelissen JJ, Blaise D.

Hematopoietic stem cell transplantation for patients with AML in first complete remission.

Blood. 2016 Jan 7;127(1):62-70. doi: 10.1182/blood-2015-07-604546. Epub 2015 Dec 10. Review.

Dinmohamed AG, Szabó A, van der Mark M, Visser O, Sonneveld P, Cornelissen JJ, Jongen-Lavrencic M, Rijneveld AW.

Improved survival in adult patients with acute lymphoblastic leukemia in the Netherlands: a population-based study on treatment, trial participation and survival.

Leukemia. 2016 Feb;30(2):310-7. doi: 10.1038/leu.2015.230. Epub 2015 Aug 19.

- CURRICULUM VITAE -

44

Brands-Nijenhuis AV, Labopin M, Schouten HC, Volin L, Socié G, Cornelissen JJ, Huynh A, Ljungman P, Malard F, Esteve J, Nagler A, Mohty M.

Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission. A retrospective survey on behalf of the ALWP of EBMT.

Haematologica. 2016 Feb;101(2):248-55. doi: 10.3324/haematol.2015.132654. Epub 2015 Nov 20.

Savani BN, Labopin M, Blaise D, Niederwieser D, Ciceri F, Ganser A, Arnold R, Afanasyev B, Vigouroux S, Milpied N, Hallek M, Cornelissen JJ, Schwerdtfeger R, Polge E, Baron F, Esteve J,

Gorin NC, Schmid C, Giebel S, Mohty M, Nagler A.

Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia - A report from the ALWP of the EBMT.

Haematologica. 2016 Feb;101(2):256-62. doi: 10.3324/haematol.2015.135699. Epub 2015 Nov 12.

Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, Bloomfield CD, Estey E, Burnett A, Cornelissen JJ, Scheinberg DA, Bouscary D, Linch DC. Acute myeloid leukaemia.

Nat Rev Dis Primers. 2016 Mar 10;2:16010. doi: 10.1038/nrdp.2016.10. Review.

Czerw T, Labopin M, Schmid C, Cornelissen JJ, Chevallier P, Blaise D, Kuball J, Vigouroux S, Garban F, Lioure B, Fegueux N, Clement L, Sandstedt A, Maertens J, Guillerm G, Bordessoule D, Mohty M, Nagler A. High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia - an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Oncotarget. 2016 May 10;7(19):27255-66.

Jongen PJ, Heerings M, Ruimscholte R, Hussaarts A, Evers S, Duyverman L, Valkenburg-Vissers J, Cornelissen J, Bos M, van Droffelaar M, Lemmens WA, Donders R, van der Zande A, Visser LH.

An intensive social cognitive program (can do treatment) in people with relapsing remitting multiple sclerosis and low disability: a randomized controlled trial protocol.

BMC Neurol. 2016 May 28;16:81

Putri RM, Fredy JW, Cornelissen JJ, Koay MS, Katsonis N. Labelling Bacterial Nanocages with Photo-switchable Fluorophores.

Chemphyschem. 2016 Jun 17;17(12):1815-8. doi: 10.1002/cphc.201600013. Epub 2016 Mar 1.

van Gelder M, van Oers MH, Alemayehu WG, Abrahamse-Testroote MC, Cornelissen JJ, Chamuleau ME, Zachée P, Hoogendoorn M, Nijland M, Petersen EJ, Beeker A, Timmers GJ, Verdonck L, Westerman M, de Weerd O, Kater AP. Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study.

Bone Marrow Transplant. 2016 Jun;51(6):799-806. doi: 10.1038/bmt.2016.9. Epub 2016 Feb 15.

Czerw T, Labopin M, Gorin NC, Giebel S, Blaise D, Meloni G, Pigneux A, Bosi A, Veelken J, Ferrara F, Schaap N, Lemoli RM, Cornelissen JJ, Beohou E, Nagler A, Mohty M. Long-term follow-up of patients with acute myeloid leukemia surviving and free of disease recurrence for at least 2 years after autologous stem cell transplantation: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Cancer. 2016 Jun 15;122(12):1880-7. doi: 10.1002/cncr.29990. Epub 2016 Mar 28.

- CURRICULUM VITAE -

45

Baron F, Ruggeri A, Beohou E, Labopin M, Sanz G, Milpied N, Michallet M, Bacigalupo A, Blaise D, Sierra J, Socié G, Cornelissen JJ, Schmid C, Giebel S, Gorin NC, Esteve J, Ciceri F, Savani BN, Mohty M, Gluckman E, Nagler A. RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT.

Oncotarget. 2016 Jul 12;7(28):43027-43038. doi: 10.18632/oncotarget.9599.

Styczynski J, Tridello G, Gil L, Ljungman P, Hoek J, Iacobelli S, Ward KN, Cordonnier C, Einsele H, Socie G, Milpied N, Veelken H, Chevallier P, Yakoub-Agha I, Maertens J, Blaise D, Cornelissen J, Michallet M, Daguindau E, Petersen E, Passweg J, Greinix H, Duarte RF, Kröger N, Dreger P, Mohty M, Nagler A, Cesaro S. Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the European Society for Blood and Marrow Transplantation.

J Clin Oncol. 2016 Jul 1;34(19):2212-20. doi: 10.1200/JCO.2015.64.2405. Epub 2016 Apr 18.

Paviglianiti A, Xavier E, Ruggeri A, Ceballos P, Deconinck E, Cornelissen JJ, Nguyen-Quoc S, Maillard N, Sanz G, Rohrlach PS, Garderet L, Volt F, Rocha V, Kroeger N, Gluckman E, Fegueux N, Mohty M. Outcomes of unrelated cord blood transplantation in patients with multiple myeloma: a

survey on behalf of Eurocord, the Cord Blood Committee of Cellular Therapy and Immunobiology Working Party, and the Chronic Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Haematologica. 2016 Sep;101(9):1120-7.

Morhayim J, van de Peppel J, Braakman E, Rombouts EW, Ter Borg MN, Dudakovic A, Chiba H, van der Eerden BC, Raaijmakers MH, van Wijnen AJ, Cornelissen JJ, van Leeuwen JP.

Osteoblasts secrete miRNA-containing extracellular vesicles that enhance expansion of human umbilical cord blood cells.

Sci Rep. 2016 Sep 2;6:32034. doi: 10.1038/srep32034.

Saraceni F, Labopin M, Gorin NC, Blaise D, Tabrizi R, Volin L, Cornelissen J, Cahn JY, Chevallier P, Craddock C, Wu D, Huynh A, Arcese W, Mohty M, Nagler A; Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT).

Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT.

J Hematol Oncol. 2016 Sep 2;9(1):79. doi: 10.1186/s13045-016-0314-x.

Sobh M, Michallet M, Gahrton G, Iacobelli S, van Biezen A, Schönland S, Petersen E, Schaap N, Bonifazi F, Volin L, Meijer E, Niederwieser D, El-Cheikh J, Tabrizi R, Fegeux N, Finke J, Bunjes D, Cornelissen J, Einsele H, Bruno B, Potter M, Fanin R, Mohty M, Garderet L, Kröger N.

Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. Leukemia. 2016 Oct;30(10):2047-2054. doi: 10.1038/leu.2016.101. Epub 2016 Apr 27.

- CURRICULUM VITAE -

46

Giebel S, Czyz A, Ottmann O, Baron F, Brissot E, Ciceri F, Cornelissen JJ, Esteve J, Gorin NC, Savani B, Schmid C, Mohty M, Nagler A. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Cancer. 2016 Oct;122(19):2941-51. doi: 10.1002/cncr.30130. Epub 2016 Jun 16. Review.

Carapito R, Jung N, Kwemou M, Untrau M, Michel S, Pichot A, Giacometti G, Macquin C, Ilias W, Morlon A, Kotova I, Apostolova P, Schmitt-Graeff A, Cesbron A, Gagne K, Oudshoorn M, van der Holt B, Labalette M, Spierings E, Picard C, Loiseau P, Tamouza R, Toubert A, Parissiadis A, Dubois V, Lafarge X, Maumy-Bertrand M, Bertrand F, Vago L, Ciceri F, Paillard C, Querol S, Sierra J, Fleischhauer K, Nagler A, Labopin M, Inoko H, von dem Borne PA, Kuball J, Ota M, Katsuyama Y, Michallet M, Lioure B, Peffault de Latour R, Blaise D, Cornelissen JJ, Yakoub-Agha I, Claas F, Moreau P, Milpied N, Charron D, Mohty M, Zeiser R, Socié G, Bahram S.

Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD.

Blood. 2016 Oct 13;128(15):1979-1986. Epub 2016 Aug 22.

Lamers CH, Wijers R, van Bergen CA, Somers JA, Braakman E, Gratama JW, Debets R, Falkenburg JH, Cornelissen JJ.

CD4+ T-cell alloreactivity toward mismatched HLA class II alleles early after double umbilical cord blood transplantation.

Blood. 2016 Oct 27;128(17):2165-2174. Epub 2016 Aug 16.

Chong GM, van der Beek MT, von dem Borne PA, Boelens J, Steel E, Kampinga GA, Span LF, Lagrou K, Maertens JA, Dingemans GJ, Gaajetaan GR, van Tegelen DW, Cornelissen JJ, Vonk AG, Rijnders BJ.

PCR-based detection of *Aspergillus fumigatus* Cyp51A mutations on bronchoalveolar lavage: a multicentre validation of the AsperGenius assay® in 201 patients with haematological disease suspected for invasive aspergillosis.

J Antimicrob Chemother. 2016 Dec;71(12):3528-3535. Epub 2016 Aug 15.

van Walraven SM, Brand A, Bakker JN, Heemskerk MB, Nillesen S, Bierings MB, Bungener LB,

Hepkema BG, Lankester A, van der Meer A, Sintnicolaas K, Somers JA, Spierings E, Tilanus MG, Voorter CE, Cornelissen JJ, Oudshoorn M.

The increase of the global donor inventory is of limited benefit to patients of non-Northwestern European descent.

Haematologica. 2017 Jan;102(1):176-183. doi: 10.3324/haematol.2016.145730. Epub 2016 Aug 25.

Versluis J, In 't Hout FE, Devillier R, van Putten WL, Manz MG, Vekemans MC, Legdeur MC, Passweg JR, Maertens J, Kuball J, Biemond BJ, Valk PJ, van der Reijden BA, Meloni G, Schouten HC, Vellenga E, Pabst T, Willemze R, Löwenberg B, Ossenkoppele G, Baron F, Huls G, Cornelissen JJ. Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.

Leukemia. 2017 Jan;31(1):26-33. doi: 10.1038/leu.2016.183. Epub 2016 Jun 24.

- CURRICULUM VITAE -

47

Poiré X, Labopin M, Maertens J, Yakoub-Agha I, Blaise D, Ifrah N, Socié G, Gedde-Dhal T, Schaap N, Cornelissen JJ, Vigouroux S, Sanz J, Michaux L, Esteve J, Mohty M, Nagler A.

Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).

J Hematol Oncol. 2017 Jan 18;10(1):20. doi: 10.1186/s13045-017-0393-3.

Versluis J, Labopin M, Ruggeri A, Socie G, Wu D, Volin L, Blaise D, Milpied N, Craddock C, Yakoub-Agha I, Maertens J, Ljungman P, Huynh A, Michallet M, Deconinck E, Chevallier P, Passweg J, Ciceri F, Mohty M, Cornelissen JJ, Nagler A.

Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. Blood Adv. 2017 Feb 28;1(7):477-485. doi: 10.1182/bloodadvances.2016002386. eCollection 2017 Feb 28.

Gorin NC, Labopin M, Czerw T, Pabst T, Blaise D, Dumas PY, Nemet D, Arcese W, Trisolini SM, Wu D, Huynh A, Zuckerman T, Meijer E, Cagirgan S, Cornelissen J, Houhou M, Polge E, Mohty M, Nagler A.

Autologous stem cell transplantation for adult acute myelocytic leukemia in first remission-Better outcomes after busulfan and melphalan compared with busulfan and cyclophosphamide: A retrospective study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

Cancer. 2017 Mar 1;123(5):824-831. doi: 10.1002/cncr.30400. Epub 2016 Dec 1.

van Gelder M, de Wreede LC, Bornhäuser M, Niederwieser D, Karas M, Anderson NS, Gramatzki M, Dreger P, Michallet M, Petersen E, Bunjes D, Potter M, Beelen D, Cornelissen JJ, Yakoub-Agha I, Russell NH, Finke J, Schoemans H, Vitek A, Urbano-Ispizua Á, Blaise D, Volin L, Chevallier P, Caballero D, Putter H, van Biezen A, Henseler A, Schönland S, Kröger N, Schetelig J.

Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation.

Bone Marrow Transplant. 2017 Mar;52(3):372-380. doi: 10.1038/bmt.2016.282. Epub 2016 Dec 12.

Tüysüz N, van Bloois L, van den Brink S, Begthel H, Verstegen MM, Cruz LJ, Hui L, van der Laan LJ, de Jonge J, Vries R, Braakman E, Mastrobattista E, Cornelissen JJ, Clevers H, Ten Berge D. Lipid-mediated Wnt protein stabilization enables serum-free culture of human organ stem cells.

Nat Commun. 2017 Mar 6;8:14578. doi: 10.1038/ncomms14578.

Dolstra H, Roeven MW, Spanholtz J, Hangalapura BN, Tordoir M, Maas F, Leenders M, Bohme F, Kok N, Trilsbeek C, Paardekooper J, van der Waart AB, Westerweel PE, Sniijders TJ, Cornelissen JJ, Bos GM, Pruijt HF, De Graaf AO, van der Reijden B, Jansen JH, van der Meer A, Huls G, Cany J, Preijers F, Blijlevens NM, Schaap NM.

Successful transfer of umbilical cord blood CD34+ hematopoietic stem and progenitor-derived NK cells in older acute myeloid leukemia patients.

Clin Cancer Res. 2017 Mar 9. pii: clincanres.2981.2016.

Canaani J, Labopin M, Socié G, Nihtinen A, Huynh A, Cornelissen J, Deconinck E, Gedde-Dahl T, Forcade E, Chevallier P, Bourhis JH, Blaise D, Mohty M, Nagler A.

Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: an analysis from the acute leukemia working party of the EBMT.

Am J Hematol. 2017 Mar 28.

- CURRICULUM VITAE -

48

Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menses HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators.

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

N Engl J Med. 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324.

Gratwohl A, Sureda A, Cornelissen J, Apperley J, Dreger P, Duarte R, Greinix HT, Mc Grath E, Kroeger N, Lanza F, Nagler A, Snowden JA, Niederwieser D, Brand R.

Alloreactivity: the Janus-face of hematopoietic stem cell transplantation.

Leukemia. 2017 Apr 7. doi: 10.1038/leu.2017.79

Canaani J, Beohou E, Labopin M, Socié G, Huynh A, Volin L, Cornelissen J, Milpied N, Gedde-Dahl T, Deconinck E, Fegueux N, Blaise D, Mohty M, Nagler A.

Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: An analysis of 1690 patients from the acute leukemia working party of EBMT.

Am J Hematol. 2017 Apr;92(4):344-350. doi: 10.1002/ajh.24640. Epub 2017 Feb 7.

Meissner J, Finel H, Dietrich S, Boumendil A, Kanfer E, Laboure G, Abecasis M, Cornelissen J, Delage J, Finke J, Hess U, Ludwig H, Mohty M, Pabst T, Pioltelli P, Robinson S, Samaras P, Montoto S, Dreger P.

Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: the European Society for Blood and Marrow Transplantation experience.

Bone Marrow Transplant. 2017 Apr;52(4):650-652. doi: 10.1038/bmt.2016.339. Epub 2016 Dec 19.

Cornelissen JJ, Kalin B, Lamers CHJ.

Graft predominance after double umbilical cord blood transplantation: a review.

Stem Cell Investig. 2017 May 26;4:47. doi: 10.21037/sci.2017.05.09. eCollection 2017. Review.

Baron F, Ruggeri A, Beohou E, Labopin M, Mohty M, Blaise D, Cornelissen JJ, Chevallier P, Sanz G, Petersen E, Savani BN, Gluckman E, Nagler A.

Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT.

J Hematol Oncol. 2017 Jun 21;10(1):128. doi: 10.1186/s13045-017-0497-9.

Canaani J, Labopin M, Socié G, Nihtinen A, Huynh A, Cornelissen J, Deconinck E, Gedde-Dahl T, Forcade E, Chevallier P, Bourhis JH, Blaise D, Mohty M, Nagler A.

Long term impact of hyperleukocytosis in newly diagnosed acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: An analysis from the acute leukemia working party of the EBMT.

Am J Hematol. 2017 Jul;92(7):653-659. doi: 10.1002/ajh.24737. Epub 2017 May 26.

Dolstra H, Roeven MWH, Spanholtz J, Hangalapura BN, Tordoir M, Maas F, Leenders M, Bohme F, Kok N, Trilsbeek C, Paardekooper J, van der Waart AB, Westerweel PE, Sniijders TJF, Cornelissen J, Bos G, Pruijt HFM, de Graaf AO, van der Reijden BA, Jansen JH, van der Meer A, Huls G, Cany J, Preijers F, Blijlevens NMA, Schaap NM.

Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients.

Clin Cancer Res. 2017 Aug 1;23(15):4107-4118. doi: 10.1158/1078-0432.CCR-16-2981. Epub 2017 Mar 9.

- CURRICULUM VITAE -

49

Gratwohl A, Sureda A, Cornelissen J, Apperley J, Dreger P, Duarte R, Greinix HT, Mc Grath E, Kroeger N, Lanza F, Nagler A, Snowden JA, Niederwieser D, Brand R.

Alloreactivity: the Janus-face of hematopoietic stem cell transplantation.
Leukemia. 2017 Aug;31(8):1752-1759. doi: 10.1038/leu.2017.79. Epub 2017 Mar 8.
 Canaani J, Savani BN, Labopin M, Michallet M, Craddock C, Socié G, Volin L, Maertens JA, Crawley C, Blaise D, Ljungman PT, Cornelissen J, Russell N, Baron F, Gorin N, Esteve J, Ciceri F, Schmid C, Giebel S, Mohty M, Nagler A.

ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT.
Am J Hematol. 2017 Aug;92(8):789-796. doi: 10.1002/ajh.24771. Epub 2017 Jun 9.
 Geelen IGP, Thielen N, Janssen JJWM, Levin MD, Hoogendoorn M, Visser O, Cornelissen JJ, Westerweel PE.

Influence of WHO versus ELN advanced phase chronic myeloid leukemia definitions on overall survival.
Eur J Haematol. 2017 Oct;99(4):381-382. doi: 10.1111/ejh.12928. Epub 2017 Aug 15.
 De Jong CN, Saes L, Klerk CPW, Van der Klift M, Cornelissen JJ, Broers AEC.

Etanercept for steroid-refractory acute graft-versus-host disease: A single center experience.
PLoS One. 2017 Oct 26;12(10):e0187184. doi: 10.1371/journal.pone.0187184. eCollection 2017.
 Scheid C, de Wreede L, van Biezen A, Koenecke C, Göhring G, Volin L, Maertens J, Finke J, Passweg J, Beelen D, Cornelissen JJ, Itälä-Remes M, Chevallier P, Russell N, Petersen E, Milpied N, Richard Espiga C, Peniket A, Sierra J, Mufti G, Crawley C, Veelken JH, Ljungman P, Cahn JY, Alessandrino EP, de Witte T, Robin M, Kröger N.

Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party.
Bone Marrow Transplant. 2017 Nov;52(11):1519-1525. doi: 10.1038/bmt.2017.171. Epub 2017 Sep 11.
 Geelen IGP, Thielen N, Janssen JJWM, Hoogendoorn M, Roosma TJA, Willemsen SP, Visser O, Cornelissen JJ, Westerweel PE.

Treatment outcome in a population-based, 'real-world' cohort of patients with chronic myeloid leukemia.
Haematologica. 2017 Nov;102(11):1842-1849. doi: 10.3324/haematol.2017.174953. Epub 2017 Aug 31.
 Geelen IGP, Thielen N, Janssen JJWM, Hoogendoorn M, Roosma TJA, Willemsen SP, Valk PJM, Visser O, Cornelissen JJ, Westerweel PE.

Impact of hospital experience on the quality of tyrosine kinase inhibitor response monitoring and consequence for chronic myeloid leukemia patient survival.
Haematologica. 2017 Dec;102(12):e486-e489. doi: 10.3324/haematol.2017.175265. Epub 2017 Aug 31.
 Roth-Guepin G, Canaani J, Ruggeri A, Labopin M, Finke J, Cornelissen JJ, Delage J, Stuhler G, Rovira M, Potter M, Stadler M, Veelken H, Cahn JY, Collin M, Beguin Y, Giebel S, Nagler A, Mohty M.

Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT.
Oncotarget. 2017 Dec 4;8(68):112972-112979. doi: 10.18632/oncotarget.22934. eCollection 2017 Dec 22.

- CURRICULUM VITAE -
 50

Bierings M, Bonfim C, Peffault De Latour R, Aljurf M, Mehta PA, Knol C, Boulad F, Tbakhi A, Esquirol A, McQuaker G, Sucak GA, Othman TB, Halkes CJM, Carpenter B, Niederwieser D, Zecca M, Kröger N, Michallet M, Risitano AM, Ehninger G, Porcher R, Dufour C; EBMT SAA WP.
 Transplant results in adults with Fanconi anaemia.
Br J Haematol. 2018 Jan;180(1):100-109. doi: 10.1111/bjh.15006. Epub 2017 Nov 2.
 Lazarevic VL, Labopin M, Depei W, Yakoub-Agha I, Huynh A, Ljungman P, Schaap N, Cornelissen JJ, Maillard N, Pioltelli P, Gedde-Dahl T, Lenhoff S, Houhou M, Esteve J, Mohty M, Nagler A.

Relatively favorable outcome after allogeneic stem cell transplantation for BCR-ABL1-positive AML: A survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT).

Am J Hematol. 2018 Jan;93(1):31-39. doi: 10.1002/ajh.24928. Epub 2017 Oct 31.

Baron F, Ruggeri A, Beohou E, Labopin M, Mohty M, Sanz J, Vigouroux S, Furst S, Bosi A, Chevallier P, Cornelissen JJ, Michallet M, Sierra J, Karakasis D, Savani BN, Gluckman E, Nagler A. Occurrence of graft-versus-host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT. J Intern Med. 2018 Feb;283(2):178-189. doi: 10.1111/joim.12696. Epub 2017 Nov 6.

Schmid C, de Wreede LC, van Biezen A, Finke J, Ehninger G, Ganser A, Volin L, Niederwieser D, Beelen D, Alessandrino P, Kanz L, Schleuning M, Passweg J, Veelken H, Maertens J, Cornelissen JJ, Blaise D, Gramatzki M, Milpied N, Yakoub-Agha I, Mufti G, Rovira M, Arnold R, de Witte T, Robin M, Kröger N.

Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation. Haematologica. 2018 Feb;103(2):237-245. doi: 10.3324/haematol.2017.168716. Epub 2017 Nov 3. Poiré X, Labopin M, Polge E, Passweg J, Craddock C, Blaise D, Cornelissen JJ, Volin L, Russell NH, Socié G, Michallet M, Fegueux N, Chevallier P, Brecht A, Hunault-Berger M, Mohty M, Esteve J, Nagler A.

Allogeneic stem cell transplantation benefits for patients 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Haematologica. 2018 Feb;103(2):256-265. doi: 10.3324/haematol.2017.178251. Epub 2017 Dec 14. Duinhouwer LE, Beije N, van der Holt B, Rijken-Schelen A, Lamers CH, Somers J, Braakman E, Cornelissen JJ.

Impaired thymopoiesis predicts for a high risk of severe infections after reduced intensity conditioning without anti-thymocyte globulin in double umbilical cord blood transplantation.

Bone Marrow Transplant. 2018 Jun. doi: 10.1038/s41409-018-0103-y. [Epub ahead of print] Ofran Y, Beohou E, Labopin M, Blaise D, Cornelissen JJ, de Groot MR, Socié G, Huynh A, Maertens J, Baron F, Mohty M, Nagler A.

Anti-thymocyte globulin for graft-versus-host disease prophylaxis in patients with intermediate- or high-risk acute myeloid leukaemia undergoing reduced-intensity conditioning allogeneic stem cell transplantation in first complete remission - a survey on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation.

Br J Haematol. 2018 Feb 21. doi: 10.1111/bjh.15131. [Epub ahead of print]

- CURRICULUM VITAE -

51

Czerw T, Labopin M, Giebel S, Socié G, Volin L, Fegueux N, Masszi T, Blaise D, Chaganti S, Cornelissen JJ, Passweg J, Maertens J, Itälä-Remes M, Wu D, Mohty M, Nagler A.

Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT.

Cancer. 2018 Jun 15. doi: 10.1002/cncr.31354. [Epub ahead of print]

Baron F, Labopin M, Ruggeri A, Cornelissen JJ, Meijer E, Sengeloev H, Niederwieser D, de Groot MR, Schouten HC, Milpied NJ, Blaise D, Savani B, Gluckman E, Mohty M, Nagler A.

Impact of donor type in patients with AML given allogeneic hematopoietic cell transplantation after low-dose TBI based regimen.

Clin Cancer Res. 2018 Jun 15. pii: clincanres.3622.2017. doi: 10.1158/1078-0432.CCR-17-3622. [Epub ahead of print]

Ruggeri A, Labopin M, Bacigalupo A, Afanasyev B, Cornelissen JJ, Elmaagacli A, Itälä-Remes M, Blaise D, Meijer E, Koc Y, Milpied N, Schouten HC, Kroeger N, Mohty M, Nagler A.

Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling

or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT. *J Hematol Oncol.* 2018 Mar 15;11(1):40. doi: 10.1186/s13045-018-0586-4.

Tozatto-Maio K, Giannotti F, Labopin M, Ruggeri A, Volt F, Paviglianiti A, Kenzey C, Hayashi H, Cornelissen J, Michallet M, Karakasis D, Deconinck E, Rohrlach PS, de la Tour RP, Blaise D, Petersen E, D'Aveni M, Sengeloev H, Lamy T, Russell NH, Forcade E, Craddock CF, Nagler A, Gluckman E, Rocha V.

Cord Blood Unit Dominance Analysis and Effect of the Winning Unit on Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee of Cellular Therapy, Immunobiology Working Party, and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Biol Blood Marrow Transplant. 2018 Mar 1. pii: S1083-8791(18)30092-2.doi:10.1016/j.bbmt.2018.02.014. [Epub ahead of print]

Geelen IGP, Thielen N, Janssen JJWM, Hoogendoorn M, Roosma TJA, Valk PJM, Visser O, Cornelissen JJ, Westerweel PE.

Omitting cytogenetic assessment from routine treatment response monitoring in chronic myeloid leukemia is safe.

Eur J Haematol. 2018 Apr;100(4):367-371. doi: 10.1111/ejh.13023. Epub 2018 Feb 7.

Craddock C, Versluis J, Labopin M, Socie G, Huynh A, Deconinck E, Volin L, Milpied N, Bourhis JH, Rambaldi A, Chevallier P, Blaise D, Manz M, Vellenga E, Vekemans MC, Maertens J, Passweg J, Vyas P, Schmid C, Löwenberg B, Ossenkoppele G, Mohty M, Cornelissen JJ, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and HOVON-SAKK.

Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia.

J Intern Med. 2018 Apr;283(4):371-379. doi: 10.1111/joim.12720. Epub 2018 Jan 5.

- CURRICULUM VITAE -

52

Schauwvlieghe AFAD, de Jonge N, van Dijk K, Verweij PE, Brüggemann RJ, Biemond BJ, Bart A, von dem Borne PA, Verbon A, van der Beek MT, Demandt AMP, Oudhuis GJ, Cornelissen JJ, van der Velden WJFM, Span LFR, Kampinga GA, Bruns AH, Vonk AG, Haas PA, Doorduyn JK, Rijnders BJA.

The diagnosis and treatment of invasive aspergillosis in Dutch haematology units facing a rapidly increasing prevalence of azole resistance. A nationwide survey and rationale for the DB-MSG 002 study protocol.

Mycoses. 2018 Apr 23. doi: 10.1111/myc.12788. [Epub ahead of print]

Halaburda K, Labopin M, Houhou M, Niederwieser D, Finke J, Volin L, Maertens J, Cornelissen JJ, Milpied N, Stuhler G, Kröger N, Esteve J, Mohty M, Nagler A.

AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation.

Bone Marrow Transplant. 2018 Apr 18. doi: 10.1038/s41409-018-0165-x. [Epub ahead of print]

Battipaglia G, Ruggeri A, Labopin M, Volin L, Blaise D, Socié G, Tabrizi R, Cornelissen JJ, Ghavamzadeh A, Huynh A, Wu D, Yakoub-Agha I, Maertens J, Chevallier P, Mohty M, Nagler A. Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia.

Bone Marrow Transplant. 2018 Apr 16. doi: 10.1038/s41409-018-0169-6. [Epub ahead of print]

Hayashi H, Ruggeri A, Volt F, Cornelissen JJ, Socié G, Sengeloev H, Michallet M, Karakasis D, Petersen E, Cahn JY, Veelken H, Mercier M, Rohrlach PS, Rafii H, Kenzey C, Xavier E, Duarte RF, Basak GW, Rocha V, Gluckman E; Eurocord and the Complications and Quality of Life WP of EBMT.

Chronic graft-versus-host disease features in double unit cord blood transplantation according to National Institutes of Health 2005 cGVHD Consensus criteria.

Bone Marrow Transplant. 2018 Apr;53(4):417-421. doi: 10.1038/s41409-017-0061-9. Epub 2018

Jan 12.

Ciurea SO, Labopin M, Socié G, Volin L, Passweg J, Chevallier P, Beelen D, Milpied N, Blaise D, Cornelissen JJ, Fegueux N, Polge E, Kongtim P, Rondon G, Esteve J, Mohty M, Savani BN, Champlin RE, Nagler A.

Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center.

Cancer. 2018 May 15;124(10):2134-2141. doi: 10.1002/cncr.31311. Epub 2018 Feb 22.

McLornan DP, Szydlo R, Robin M, van Biezen A, Koster L, Blok HJP, Van Lint MT, Finke J, Vitek A, Carlson K, Griskevicius L, Holler E, Itälä-Remes M, Schaap M, Socié G, Bay JO, Beguin Y, Bruno B, Cornelissen JJ, Gedde-Dahl T, Ljungman P, Rubio MT, Yakoub-Agha I, Klyuchnikov E, Olavarria E, Chalandon Y, Kröger N.

Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT. Br J Haematol. 2018 May 29. doi: 10.1111/bjh.15407. [Epub ahead of print]

Shouval R, de Jong CN, Fein J, Broers AEC, Danylesko I, Shimoni A, Reurs MR, Baars AE, van der Schaft N, Nagler A, Cornelissen JJ.

Baseline Renal Function and Albumin are Powerful Predictors for Allogeneic Transplantation-Related Mortality. Biol Blood Marrow Transplant. 2018 Aug;24(8):1685-1691. doi: 10.1016/j.bbmt.2018.05.005. Epub 2018 May 9.

Robin M, Porcher R, Ruggeri A, Blaise D, Wolschke C, Koster L, Angelucci E,

- CURRICULUM VITAE -

53

Stölzel F, Potter V, Yakoub-Agha I, Koc Y, Ciceri F, Finke J, Labussière-Wallet H, Cascon MJP, Verbeek M, Rambaldi A, Cornelissen JJ, Chevallier P, Radia R, Nagler A, Fegueux N, Gluckman E, de Witte T, Kröger N.

HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis. Biol Blood Marrow Transplant. 2018 Aug 30. pii: S1083-8791(18)30528-7. doi: 10.1016/j.bbmt.2018.08.026. [Epub ahead of print]

Geelen IGP, Sandin F, Thielen N, Janssen JJWM, Hoogendoorn M, Visser O, Cornelissen JJ, Hoglund M, Westerweel PE. Validation of the EUTOS long-term survival score in a recent independent cohort of "real world" CML patients. Leukemia. 2018 Oct;32(10):2299-2303. doi: 10.1038/s41375-018-0136-7. Epub 2018

Apr 19.

Lorentino F, Labopin M, Bernardi M, Ciceri F, Socié G, Cornelissen JJ, Esteve J, Ruggeri A, Volin L, Yacoub-Agha I, Craddock C, Passweg J, Blaise D, Gedde-Dahl T, Poiani M, Fegueux N, Mohty M, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse

karyotype AML in first complete remission. Am J Hematol. 2018 Oct;93(10):1236-1244. doi: 10.1002/ajh.25231. Epub 2018 Sep 3.

Kalin B, Pijnappel EN, van Gelder M, Visser O, van de Loosdrecht AA,

Ossenkoppele GJ, Cornelissen JJ, Dinmohamed AG, Jongen-Lavrencic M. Intensive treatment and trial participation in elderly acute myeloid leukemia patients: A

population-based analysis in The Netherlands. Cancer Epidemiol. 2018 Oct 19;57:90-96. doi: 10.1016/j.canep.2018.09.007. [Epub ahead of print]

Belkacemi Y, Labopin M, Giebel S, Loganadane G, Miszczyk L, Michallet M, Socié G, Schaap NPM, Cornelissen JJ, Yakoub-Agha I, Polge E, Mohty M, Gorin NC, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow

Transplantation (EBMT). Single-Dose Daily Fractionation Is Not Inferior to Twice-a-Day Fractionated Total-Body Irradiation Before Allogeneic Stem Cell Transplantation for Acute Leukemia: A Useful Practice Simplification Resulting From the SARASIN Study. Int J Radiat Oncol Biol Phys. 2018 Nov 1;102(3):515-526.

doi: 10.1016/j.ijrobp.2018.06.015. Epub 2018 Jun 19.

MT, Finke J, Vitek A, Carlson K, Griskevicius L, Holler E, Itälä-Remes M, Schaap M, Socié G, Bay JO, Beguin Y, Bruno B, Cornelissen JJ, Gedde-Dahl T, Ljungman P, Rubio MT, Yakoub-Agha I, Klyuchnikov E, Olavarria E, Chalandon Y, Kröger N. Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT.

Br J Haematol. 2018 Aug;182(3):418-422.

Shouval R, de Jong CN, Fein J, Broers AEC, Danylesko I, Shimoni A, Reurs MR, Baars AE, van der Schaft N, Nagler A, Cornelissen JJ. Baseline Renal Function and Albumin are Powerful Predictors for Allogeneic Transplantation-Related Mortality. Biol Blood Marrow Transplant. 2018 Aug;24(8):1685-1691.

Schauwvlieghe AFAD, de Jonge N, van Dijk K, Verweij PE, Brüggemann RJ, Biemond BJ, Bart A, von dem Borne PA, Verbon A, van der Beek MT, Demandt AMP, Oudhuis GJ, Cornelissen JJ, van der Velden WJFM, Span LFR, Kampinga GA, Bruns AH, Vonk AG, Haas PA, Doorduyn JK, Rijnders BJA. The diagnosis and treatment of invasive aspergillosis in Dutch haematology units facing a rapidly increasing prevalence of azole-resistance. A nationwide survey and rationale for the DB-MSG 002 study protocol.

Mycoses. 2018 Sep;61(9):656-664.

Geelen IGP, Sandin F, Thielen N, Janssen JJWM, Hoogendoorn M, Visser O, Cornelissen JJ, Hoglund M, Westerweel PE. Validation of the EUTOS long-term survival score in a recent independent cohort of "real world" CML patients. Leukemia. 2018 Oct;32(10):2299-2303.

Kalin B, Pijnappel EN, van Gelder M, Visser O, van de Loosdrecht AA, Ossenkuppele GJ, Cornelissen JJ, Dinmohamed AG, Jongen-Lavrencic M. Intensive treatment and trial participation in elderly acute myeloid leukemia patients: A population-based analysis in The Netherlands. Cancer Epidemiol. 2018 Dec;57:90-96.

Robin M, Porcher R, Ruggeri A, Blaise D, Wolschke C, Koster L, Angelucci E, Stölzel F, Potter V, Yakoub-Agha I, Koc Y, Ciceri F, Finke J, Labussiére-Wallet H, Cascon MJP, Verbeek M, Rambaldi A, Cornelissen JJ, Chevallier P, Radia R, Nagler A, Fegueux N, Gluckman E, de Witte T, Kröger N.

HLA-Mismatched Donors in Patients with Myelodysplastic Syndrome: An EBMT Registry Analysis. Biol Blood Marrow Transplant. 2019 Jan;25(1):114-120.

Ofran Y, Beohou E, Labopin M, Blaise D, Cornelissen JJ, de Groot MR, Socié G, Huynh A, Maertens J, Baron F, Mohty M, Nagler A. Anti-thymocyte globulin for graft-versus-host disease prophylaxis in patients with intermediate- or high-risk acute myeloid leukaemia undergoing reduced-intensity conditioning allogeneic stem cell transplantation in first complete remission - a survey on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. Br J Haematol. 2019 Feb;184(4):643-646.

Versluis J, Cornelissen JJ. Risks and benefits in a personalized application of allogeneic transplantation in patients with AML in first CR. Semin Hematol.

2019 Apr;56(2):164-170.

Polak R, Bierings MB, van der Leije CS, Sanders MA, Roovers O, Marchante JRM, Boer JM, Cornelissen JJ, Pieters R, den Boer ML, Buitenhuis M.

Autophagy Inhibition as a Potential Future Targeted Therapy for Etv6-Runx1 Driven B-Cell Precursor Acute Lymphoblastic Leukemia. Haematologica. 2019 Apr;104(4):738-748.

Baron F, Labopin M, Ruggeri A, Volt F, Mohty M, Blaise D, Chevallier P, Sanz J, Fegueux N, Cornelissen JJ, Rambaldi A, Savani BN, Gluckman E, Nagler A. Cord

blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukaemia in first remission.

J Intern Med. 2019 Apr;285(4):446-454.

Geneugelijck K, Thus KA, van Deutekom HWM, Calis JJA, Borst E, Kemir C, Oudshoorn M, van der Holt B, Meijer E, Zeerleder S, de Groot MR, von dem Borne PA, Schaap N, Cornelissen J, Kuball J, Spierings E.

Exploratory Study of Predicted Indirectly ReCognizable HLA Epitopes in Mismatched Hematopoietic Cell Transplantations.

Front Immunol. 2019 Apr 24;10:880.

Poiré X, Labopin M, Polge E, Forcade E, Ganser A, Volin L, Michallet M, Blaise D, Yakoub-Agha I, Maertens J, Richard Espiga C, Cornelissen J, Finke J, Mohty M, Esteve J, Nagler A; Acute Leukemia Working Party of the EBMT.

Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT.

Haematologica. 2019 May 2;haematol.2019.216168.

Von Felden J, Alric L, Pischke S, Aitken C, Schlabe S, Spengler U, Giordani MT, Schnitzler P, Bettinger D, Thimme R, Xhaard A, Binder M, Ayuk F, Lohse AW, Cornelissen JJ, de Man RA, Mallet V. The burden of hepatitis E among patients with haematological malignancies: A retrospective European cohort study. J

Hepatol. 2019 May 18. pii: S0168-8278(19)30290-9.

Gagelmann N, Eikema DJ, Stelljes M, Beelen D, de Wreede L, Mufti G, Knelange NS, Niederwieser D, Friis LS, Ehnninger G, Nagler A, Yakoub-Agha I, Meijer E, Ljungman P, Maertens J, Kanz L, Lopez-Corral L, Brecht A, Craddock C, Finke J, Cornelissen JJ, Bernasconi P, Chevallier P, Sierra J, Robin M, Kroger N.

Optimized Ebmt Transplant-Specific Risk Score in Myelodysplastic Syndromes after Allogeneic Stem-Cell Transplantation.

Haematologica. 2019 May;104(5):929-936.

Gagelmann N, Eikema DJ, de Wreede LC, Koster L, Wolschke C, Arnold R, Kanz L, McQuaker G, Marchand T, Socié G, Bourhis JH, Mohty M, Cornelissen JJ, Chevallier P, Bernasconi P, Stelljes M, Rohrlach PS, Fanin R, Finke J, Maertens J, Blaise D, Itälä-Remes M, Labussière-Wallet H, Robin M, McLornan D, Chalandon Y, Yakoub-Agha I, Kröger N; CMWP of the European Society for Blood and Marrow Transplantation.

Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation.

Biol Blood Marrow Transplant. 2019 Jun;25(6):e204-e208.

Robin M, Chevret S, Koster L, Wolschke C, Yakoub-Agha I, Bourhis JH, Chevallier P, Cornelissen JJ, Reményi P, Maertens J, Poiré X, Craddock C, Socié G, Itälä-Remes M, Schouten HC, Marchand T, Passweg J, Blaise D, Damaj G, Ozkurt ZN, Zuckerman T, Cluzeau T, Labussière-Wallet H, Cammenga J, McLornan D, Chalandon Y, Kröger N. Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis.

Haematologica. 2019 Jun;104(6):1230-1236.

De Greef GE, Braakman E, van der Holt B, Janssen J, Petersen E, Vucinic V, Thuss N, Grootes M, Cornelissen JJ.

The Feasibility and Efficacy of Subcutaneous Plerixafor for Mobilization of Peripheral Blood Stem Cells in Allogeneic Hla-Identical Sibling Donors: Results of the Hovon-107 Study.

Transfusion. 2019;59(1):316-24.

Giebel S, Marks DI, Boissel N, Baron F, Chiaretti S, Ciceri F, Cornelissen JJ, Doubek M, Esteve J, Fielding A, Foa R, Gorin NC, Gökbüget N, Hallböök H, Hoelzer D, Paravichnikova E, Ribera JM, Savani B, Rijneveld AW, Schmid C, Wartiovaara-Kautto U, Mohty M, Nagler A, Dombret H.

Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

Bone Marrow Transplant. 2019 Jun;54(6):798-809.

Schmidt-Hieber M, Tridello G, Ljungman P, Mikulska M, Knelange N, Blaise D, Socié G, Volin L, Blijlevens N, Fegueux N, Yakoub-Agha I, Forcade E, Maertens J, Chevallier P, Passweg J, Cornelissen J, Russell N, Craddock C, Bourhis JH, Marchand T, Reményi P, Cahn JY, Michallet M, Montoto S, Kröger N, Glaß B, Styczynski J.

The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT.

Ann Hematol. 2019 Jul;98(7):1755-1763.

Nagler A, Labopin M, Dholaria B, Niittyvuopio R, Maertens J, Poiré X, Cornelissen J, Reményi P, Bourhis JH, Beguin Y, Malladi R, Kerre T, Schroyens W, Savani BN, Mohty M.

Impact of antithymocyte globulin on outcomes of allogeneic hematopoietic cell transplantation with TBI.

Blood Adv. 2019 Jul 9;3(13):1950-1960.

Westerweel PE, Te Boekhorst PAW, Levin MD, Cornelissen JJ.

New Approaches and Treatment Combinations for the Management of Chronic Myeloid Leukemia. Front

Oncol. 2019 Aug 6;9:665.

Kalin B, Ter Borg M, Wijers R, Somers JAE, van der Holt B, van Bergen CAM, Petersen EJ, Kuball J, Meijer E, Schaap NPM, Zeerleder SS, Broers AE, Braakman E, Falkenburg JHF, Lamers CHJ, Cornelissen JJ.

Double Umbilical Cord Blood Transplantation in High-Risk Hematological Patients: A Phase II Study Focusing on the Mechanism of Graft Predominance.

Hemasphere. 2019 Aug 9;3(5):e285.

Gratwohl A, Duarte R, Snowden JA, van Biezen A, Baldomero H, Apperley J, Cornelissen J, Greinix HT, Grath EM, Mohty M, Kroeger N, Nagler A, Niederwieser D, Putter H, Brand R; Joint Accreditation Committee JACIE.

Pre-transplantation Risks and Transplant-Techniques in Haematopoietic Stem Cell Transplantation for Acute Leukaemia.

EClinicalMedicine. 2019 Aug 9;15:33-41.

Halaburda K, Labopin M, Mailhol A, Socié G, Craddock C, Aljurf M, Beelen D, Cornelissen JJ, Bourhis JH, Labussière-Wallet H, Blaise D, Gedde-Dahl T, Gilleece M, Yakoub-Agha I, Mufti G, Esteve J, Mohty M, Nagler A.

Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Haematologica. 2019 Aug 22. pii: haematol.2019.222810.

Canaani J, Labopin M, Itälä-Remes M, Blaise D, Socié G, Forcade E, Maertens J, Wu D, Malladi R, Cornelissen JJ, Huynh A, Bourhis JH, Esteve J, Mohty M, Nagler A.

Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia.

Leukemia. 2019 Aug;33(8):1944-1952.

Resendiz-Sharpe A, Mercier T, Lestrade PPA, van der Beek MT, von dem Borne PA, Cornelissen JJ, De Kort E, Rijnders BJA, Schauwvlieghe AFAD, Verweij PE, Maertens J, Lagrou K.

Prevalence of voriconazole-resistant invasive aspergillosis and its impact on mortality in haematology patients.

J Antimicrob Chemother. 2019 Sep 1;74(9):2759-2766.

Bazarbachi A, Labopin M, Battipaglia G, Djabali A, Passweg J, Socié G, Forcade E, Blaise D, Chevallier P, Orvain C, Cornelissen JJ, Arcese W, Chantepie S, Hashaishi K, El Cheikh J, Medinger M, Esteve J, Nagler A, Mohty M. Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party.

Haematologica. 2019 Sep;104(9):e398-e401.

Heinicke T, Labopin M, Polge E, Niederwieser D, Platzbecker U, Sengelov H, Choi G, Cornelissen J, Blaise D, Kuball J, van Gorkom G, Schaap N, Potter V, Paul F, Savani BN, Nagler A, Mohty M. Fludarabine/busulfan versus fludarabine/total-body-irradiation (2Gy) as conditioning prior to allogeneic stem cell transplantation in patients (60 years) with acute myelogenous leukemia: a study of the acute leukemia working party of the EBMT.

Bone Marrow Transplant. 2019 Oct 23;10.1038/s41409-019-0720-0.

Schauwvlieghe AFAD, Buil JB, Verweij PE, Hoek RAS, Cornelissen JJ, Blijlevens NMA, Henriët SSV, Rijnders BJA, Brüggemann RJM. High-dose posaconazole for azole-resistant aspergillosis and other difficult-to-treat mould infections. Mycoses. 2019 Oct 29.

Chhatta AR, Cordes M, Hanegraaf MAJ, Vloemans S, Cupedo T, Cornelissen JJ, Carlotti F, Salvatori D, Pike-Overzet K, Fibbe WE, Hoeben RC, Mikkers HMM, Staal FJT. De novo generation of a functional human thymus from induced pluripotent stem cells. J Allergy Clin Immunol. 2019 Nov;144(5):1416-1419.e7.

Cohen S, Roy J, Lachance S, Delisle JS, Marinier A, Busque L, Roy DC, Barabé F, Ahmad I, Bambace N, Bernard L, Kiss T, Bouchard P, Caudrelier P, Landais S, Larochelle F, Chagraoui J, Lehnertz B, Corneau S, Tomellini E, van Kampen JJA, Cornelissen JJ, Dumont-Lagacé M, Tanguay M, Li Q, Lemieux S, Zandstra PW, Sauvageau G. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study. Lancet Haematol. 2019 Nov 5. pii: S2352-3026(19)30202-9.

Michallet M, Dreger P, Sobh M, Koster L, Hoek J, Boumendil A, Scheid C, Fox CP, Wulf G, Krüger W, van Gelder M, Corradini P, Russo D, Passweg J, Schoemans H, Bethge W, Schaap N, Cornelissen J, Browne P, Durakovic N, Muller L, Montoto S, Kroger N, Schetelig J; French Cooperative Group for CLL, SFGM-TC, and the EBMT Chronic Malignancy and Lymphoma Working Parties. Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia. Bone Marrow Transplant. 2019 Nov 7;10.1038/s41409-019-0742-7.

Passweg JR, Labopin M, Christopheit M, Cornelissen J, Pabst T, Socié G, Russel N, Yakoub-Agha I, Blaise D, Gedde-Dahl T, Labussière-Wallet H, Malladi R, Forcade E, Maury S, Polge E, Lanza F, Gorin NC, Mohty M, Nagler A. Postremission Consolidation by Autologous Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia in First Complete Remission (CR) and Negative Implications for Subsequent Allogeneic HCT in Second CR: A Study by the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Biol Blood Marrow Transplant. 2019 Nov 21;S1083-8791(19)30788-8

Shimoni A, Labopin M, Savani B, Byrne M, Volin L, Finke J, Niederwieser D, Ehninger G, Blaise D, Beelen D, Tabrizi R, Sengeloev H, Ganser A, Cornelissen JJ, Mohty M, Nagler A. Comparable Long-Term Outcome after Allogeneic Stem Cell Transplantation from Sibling and Matched Unrelated Donors in Patients with Acute Myeloid Leukemia Older Than 50 Years: A Report on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2019 Nov;25(11):2251-2260.

Poiré X, Labopin M, Polge E, Volin L, Finke J, Ganser A, Blaise D, Yakoub-Agha I, Beelen D, Forcade E, Lioure B, Socié G, Niederwieser D, Labussière-Wallet H, Maertens J, Cornelissen J, Craddock C, Mohty M, Esteve J, Nagler A.

The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLA-matched allogeneic stem cell transplantation.

Am J Hematol. 2019 Dec 26;10.1002/ajh.25714.

Ruggeri A, Labopin M, Savani B, Paviglianiti A, Blaise D, Volt F, Ciceri F, Bacigalupo A, Tischer J, Chevallier P, Koc Y, Cornelissen JJ, Ehninger G, Sanz G, Deconinck E, Rocha V, Baron F, Mohty M, Gluckman E, Nagler A.

Hematopoietic stem cell transplantation with unrelated cord blood or haploidentical donor grafts in adult patients with secondary acute myeloid leukemia, a comparative study from Eurocord and the ALWP EBMT.

Bone Marrow Transplant. 2019 Dec;54(12):1987-1994.

Styczynski J, Tridello G, Gil L, Ljungman P, Mikulska M, Ward KN, Cordonnier C, de la Camara R, Averbuch D, Knelange N, Socié G, Chevallier P, Blaise D, Yakoub-Agha I, Forcade E, Cornelissen J, Maertens J, Petersen E, Nguyen-Quoc S, Veelken H, Schaap N, Passweg J, Michallet M, Fegueux N, Deconinck E, Russell N, Basak G, Bader P, Montoto S, Kröger N, Cesaro S; Infectious Diseases Working Party EBMT.

Prognostic impact of EBV serostatus in patients with lymphomas or chronic malignancies undergoing allogeneic HCT.

Bone Marrow Transplant. 2019 Dec;54(12):2060-2071.

Gilleece MH, Labopin M, Savani BN, Yakoub-Agha I, Socié G, Gedde-Dahl T, Blaise D, Byrne JL, Craddock C, Cornelissen JJ, Arcese W, Forcade E, Crawley C, Polge E, Mohty M, Nagler A.

Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT.

Leukemia. 2020 Jan;34(1):87-99.

Cornelissen JJ. Article ID: FSB220364, Article DOI: 10.1096/fj.201902610R, Internal Article ID: 16690140

Article: Identification of osteolineage cell-derived extracellular vesicle cargo implicated in hematopoietic support

Journal: The FASEB Journal; Febr. 2020

Cohen S, Roy J, Lachance S, Delisle JS, Marinier A, Busque L, Roy DC, Barabé F, Ahmad I, Bambace N, Bernard L, Kiss T, Bouchard P, Caudrelier P, Landais S, Laroche F, Chagraoui J, Lehnertz B, Corneau S, Tomellini E, van Kampen JJA, Cornelissen JJ, Dumont-Lagacé M, Tanguay M, Li Q, Lemieux S, Zandstra PW, Sauvageau G.

Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study.

Lancet Haematol. 2020 Feb;7(2):e134-e145.

Schauwvlieghe AFAD, Buil JB, Verweij PE, Hoek RAS, Cornelissen JJ, Blijlevens NMA, Henriët SSV, Rijnders BJA, Brüggemann RJM.

High-dose posaconazole for azole-resistant aspergillosis and other difficult-to-treat mould infections.

Mycoses. 2020 Feb;63(2):122-130.

Kalin B, Metafuni E, Ter Borg M, Wijers R, Braakman E, Lamers CHJ, Bacigalupo A, Cornelissen JJ.

CD4+ T-cell alloreactivity after haploidentical hematopoietic stem cell transplantation

Haematologica. 2020 Mar 12;haematol.2019.244152.

Van der Straten L, Levin MD, Visser O, Blijlevens NMA, Cornelissen JJ, Doorduijn JK, Kater AP, Dinmohamed AG.

The effectiveness of ibrutinib in chronic lymphocytic leukaemia: a nationwide, population-based study in the Netherlands. Br J Haematol. 2020 Mar;188(6):e109-e112.

Morhayim J, Ghebes CA, Erkeland SJ, Ter Borg MND, Hoogenboezem RM, Bindels EMJ, van Alphen FPJ, Kasseem M, van Wijnen AJ, Cornelissen JJ, van Leeuwen JP, van der Eerden BCJ,

Voermans C, van de Peppel J, Braakman E.

Identification of osteolineage cell-derived extracellular vesicle cargo implicated in hematopoietic support.

Version 2. *FASEB J.* 2020 Apr;34(4):5435-5452.

Hernández-Boluda JC, Pereira A, Kröger N, Beelen D, Robin M, Bornhäuser M, Angelucci E, Vitek A, Blau IW, Niittyvuopio R, Finke J, Cornelissen JJ, Passweg J, Dreger P, Petersen E, Kanz L, Sanz J, Zuckerman T, Zinger N, Iacobelli S, Hayden P, Czerw T, McLornan D, Yakoub-Agha I.

Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. *Leukemia.* 2020 Apr 14.

Sanz J, Galimard JE, Labopin M, Afanasyev B, Angelucci E, Ciceri F, Blaise D, Cornelissen JJ, Meijer E, Diez-Martin JL, Koc Y, Rovira M, Castagna L, Savani B, Ruggeri A, Nagler A, Mohty M; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT.

J Hematol Oncol. 2020 May 6;13(1):46.

Lorentino F, Labopin M, Ciceri F, Vago L, Fleischhauer K, Afanasyev B, Kröger N, Cornelissen JJ, Lovira M, Meijer E, Vitek A, Elmaagacli A, Blaise D, Ruggeri A, Chabannon C, Nagler A, Mohty M; Acute Leukemia Working Party (ALWP) and Cellular Therapy and Immunobiology Working Party (CTIWP) of the European Society for Blood and Marrow Transplantation (EBMT).

Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia.

Leukemia. 2020 May 14.

Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, Socié G, Platzbecker U, Beelen D, Milpied N, Cornelissen JJ, Ganser A, Huynh A, Griskevicius L, Giebel S, Aljurf M, Brissot E, Malard F, Esteve J, Peric Z, Baron F, Ruggeri A, Schmid C, Gilleece M, Gorin NC, Lanza F, Shouval R, Versluis J, Bug G, Fløisand Y, Ciceri F, Sanz J, Bazarbachi A, Nagler A, Mohty M.

Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. *Bone Marrow Transplant.* 2020 Jun;55(6):1114-1125.

Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, Socié G, Platzbecker U, Beelen D, Milpied N, Cornelissen JJ, Ganser A, Huynh A, Griskevicius L, Giebel S, Aljurf M, Brissot E, Malard F, Esteve J, Peric Z, Baron F, Ruggeri A, Schmid C, Gilleece M, Gorin NC, Lanza F, Shouval R, Versluis J, Bug G, Fløisand Y, Ciceri F, Sanz J, Bazarbachi A, Nagler A, Mohty M.

Correction: Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. *Bone Marrow Transplant.* 2020 Jun;55(6):1213.

Halaburda K, Labopin M, Mailhol A, Socié G, Craddock C, Aljurf M, Beelen D, Cornelissen JJ, Bourhis JH, Labussière-Wallet H, Blaise D, Gedde-Dahl T, Gilleece M, Yakoub-Agha I, Mufti G, Esteve J, Mohty M, Nagler A.

Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. *Haematologica.* 2020 Jun;105(6):1723-1730.

Brissot E, Labopin M, Moiseev I, Cornelissen JJ, Meijer E, Van Gorkom G, Rovira M, Ciceri F, Griskevicius L, Blaise D, Forcade E, Mistrik M, Mielke S, Bulabois CE, Niittyvuopio R, Deconinck E, Ruggeri A, Sanz J, Spyridonidis A, Savani B, Giebel S, Nagler A, Mohty M.

Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors.

J Hematol Oncol. 2020 Jul 3;13(1):87.

Carapito R, Aouadi I, Pichot A, Spinnhirny P, Morlon A, Kotova I, Macquin C, Rolli V, Cesbron A, Gagne K, Oudshoorn M, van der Holt B, Labalette M, Spierings E, Picard C, Loiseau P, Tamouza R, Toubert A, Parissiadis A, Dubois V, Paillard C, Maumy-Bertrand M, Bertrand F, von dem Borne PA,

Kuball JHE, Michallet M, Lioure B, Peffault de Latour R, Blaise D, Cornelissen JJ, Yakoub-Agha I, Claas F, Moreau P, Charron D, Mohty M, Morishima Y, Socié G, Bahram S.

Compatibility at amino acid position 98 of MICB reduces the incidence of graft-versus-host disease in conjunction with the CMV status. *Bone Marrow Transplant.* 2020 Jul;55(7):1367-1378.

Projects

Research projects:

1996-1997 Integraal Kankercentrum Rotterdam

Development of a quantitative PCR for the detection of the bcr/abl chimeric oncogene to monitor minimal residual disease in chronic myeloid leukemia.

1996-1997 Roche Research grant

Development of a long term culture assay to study anti-proliferative effects of Interferon-alpha on chronic myeloid leukemia hematopoietic progenitor cells.

1999-2003 Koningin Wilhelmina Fonds /NKB 1999.

Cognitive sequelae and quality of life following bone marrow transplantation for hematological malignancies.

M.J. v.d. Bent, J.J. Cornelissen, A.R. van Gool.

2002-2006 Landsteiner Stichting voor Bloedtransfusie Research. 2001.

Improving T-cell recovery after allogeneic stem cell transplantation by IL-7 and restoration of thymic function.

J.J. Cornelissen, H. Spits.

2002-2006 Koningin Wilhelmina Fonds/NKB 2002

Cytokine accelerated T-cell recovery after allogeneic stem cell transplantation: experimental studies in mice with an emphasis on IL-7.

J.J. Cornelissen, E. Braakman, H. Spits.

2003-2007 Landsteiner Stichting voor Bloedtransfusie Research. 2002.

Dendritic cell-based induction of donor alloantigen-specific tolerance in allogeneic stem cell transplantation.

E. Braakman, J.J. Cornelissen, P.J.M. Leenen.

2004-2006 Erasmus University Medical Center/Revolving Fund 2004

Identification of patients at high-risk for viral reactivation after allogeneic hematopoietic stem cell transplantation by viral specific immune-monitoring.

R.A. Brooimans, J.W. Gratama, J.J. Cornelissen.

2004-2008 Landsteiner Stichting voor Bloedtransfusie Research. 2003.

Adoptive transfer of T-cells equipped with anti-CMV T-cell receptors in a human/mouse SCID chimera model to study human anti-viral immuneresponses.

H. Spits, J.J. Cornelissen, T. Schumacher.

2005-2009 Koningin Wilhelmina Fonds/ NKB 2005.

Early pathogenesis and intervention in Epstein-Barr Virus (EBV) driven post-transplant lymphoproliferative disease in SOT and SCT recipients.

J.M. Middeldorp, J.J. Cornelissen.

2006-2010 Wijnand M Pon. Stichting

Development of thymic regenerative therapy

J.J. Cornelissen, B. Löwenberg

20082010 Stichting Vanderes

Preventie van Graft-versus-Host ziekte na hematopoietische stamceltransplantatie door selectieve expansie van regulatoire T-cellen.

E. Braakman, J.J. Cornelissen.

2009-2011 Dutch Cancer Society

Discontinuation of imatinib in patients with CML in continuous complete molecular remission, VUMC 2008-4194.

G.J. Ossenkoppele, G.J. Schuurhuis, J.J. Cornelissen.

2010-2016 TI-Pharma, BMM, CTMM, Joint Program.

The ProGraft Study.

Optimising the applicability of stem cell therapy: improving cord blood stem cell homing and engraftment by liposome complexed Wnt and molecular imaging.

Investigators: Erasmus MC: J.J. Cornelissen, D. Ten Berge, E. Braakman, M. Bernsen, Utrecht University: E. Mastrobattista, Glycostem Inc: D. Groenewegen, GE-Healthcare Inc: R. van Aken. 2010-2015 Erasmus Stem Cell Institute, Translational Program,

J.J. Cornelissen, J.H. van Leeuwen

Expansion of cord blood derived hematopoietic stem cells.

2014-2015 Erasmus MC MRACE Grant.

Graft predominance after double cord blood transplantation.

2016-2020 Erasmus Stem Cell Institute.

Graft versus Leukemia effects after allogeneic hematopoietic stem cell transplantation.

Memberships

- European Cooperative Group on Bone Marrow Transplantation (Acute Leukemia Working Party; Chronic Leukemia Working Party) (EBMT)
- American Federation for Clinical Research (AFCR)
- American Society of Hematology (ASH)
- Netherlands Society for Hematology (NVvH)
- Netherlands Society for Internal Medicine (NIV)
- Royal Dutch Association of Physicians (KNMG)
- Dutch Cooperative Group HOVON, working groups Leukemia and Hematopoietic Stem Cell transplantation
- Royal Holland Society of Sciences and Humanities (Koninklijke Hollandsche Maatschappij der Wetenschappen KHMW)

Other Relevant Information

Functions in Committees:

1993-1994: Chairman of the Committee on Cytotoxic Drugs, University Hospital Utrecht

1994-1998: Member of the Committee on Hospital Drugs, Daniel den Hoed Cancer Center, Rotterdam

1995-1998: Member of the Staff Board, Daniel den Hoed Cancer Center, Rotterdam

2000-2012: Board member Dutch Society of Hematology

2006- : Chairman Working Group Stem Cell Transplantation of HOVON

2006-2010: Chairman Adviesraad Patientenzorg Erasmus MC, Rotterdam

2010-2015: Member Scientific Advisory Council MRACE, Erasmus MC

2000- : Member acute leukemia working party (ALWP) from the European Group for Blood and Marrow Transplantation (EBMT)

2008-2011: Executive board member (Treasurer) European Group for Blood and Marrow Transplantation (EBMT)

2013: Member site visit committee, Anthony Nolan, Bone Marrow Donors UK

2014- : Chairman of HOVON (the Haemato Oncology Foundation for Adults in the Netherlands)

2015-Nov. 2020: Consultant in the Data and Safety Monitoring Board of Medigene AG in CD-FDC-001, a phase I/II clinical study in patients with AML

2016- : Member of the Supervisory Board of Matchis

2016-Nov. 2020: Consultant in the Data and Safety Monitoring Board of Daiichi Sankyo, Inc. in AC220, a phase III study in patients with AML

Scientific Committees:

1998 Scientific program committee of the 3rd meeting of the European Hematology Association (EHA) and 27th Congress of the International Society of Hematology (Amsterdam, the Netherlands)

1999 Education Program HOVON (Hematology-oncology for adult patients in The Netherlands) biannual meeting

2000, 2001 Scientific program committee of the annual meeting of the Dutch Society of Hematology

2001 Scientific program committee of the 27th meeting of the European Group for Blood and Marrow Transplantation (Maastricht, the Netherlands)

2003, 2005 Scientific program committee of the Erasmus Workshops in Leukemia (Rotterdam, the Netherlands)

2005-2011 Board member CKTO (Committee of the Dutch Cancer Society dedicated to review Prospective Clinical Studies in Cancer patients)
2006-2012 Scientific Council Dutch Cancer Foundation
2008-2010 Scientific Program Committee of the European Hematology Association
2010- Scientific Advisory Board (MRACE) ErasmusMC
2010- Gerrit Jan Mulder Foundation, chairman
2011 Member site visit committee, Stem Cell Institute Edinburgh
2014- Preparation and evaluation Dutch Hematology Congress Meetings
2015 Member site visit committee National Cancer Research Institute (NCRI), Hematology-oncology working Groups